US20210363487A1 - Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells - Google Patents
Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells Download PDFInfo
- Publication number
- US20210363487A1 US20210363487A1 US17/345,773 US202117345773A US2021363487A1 US 20210363487 A1 US20210363487 A1 US 20210363487A1 US 202117345773 A US202117345773 A US 202117345773A US 2021363487 A1 US2021363487 A1 US 2021363487A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cardiac
- human
- culture
- cfs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001054 cardiac fibroblast Anatomy 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 86
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims description 30
- 230000004069 differentiation Effects 0.000 title abstract description 55
- 210000004027 cell Anatomy 0.000 claims abstract description 185
- 230000000747 cardiac effect Effects 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 238000003501 co-culture Methods 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 46
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 41
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 41
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 41
- 239000001963 growth medium Substances 0.000 claims description 36
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 32
- 230000011664 signaling Effects 0.000 claims description 30
- 102000013814 Wnt Human genes 0.000 claims description 25
- 108050003627 Wnt Proteins 0.000 claims description 25
- 210000000130 stem cell Anatomy 0.000 claims description 25
- 210000003716 mesoderm Anatomy 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000036982 action potential Effects 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010003119 arrhythmia Diseases 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 230000002332 fibrillatory effect Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 230000001133 acceleration Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000012423 maintenance Methods 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 description 76
- 239000002609 medium Substances 0.000 description 60
- 210000002950 fibroblast Anatomy 0.000 description 51
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 26
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 26
- 101150090422 gsk-3 gene Proteins 0.000 description 26
- 210000002216 heart Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000015735 Beta-catenin Human genes 0.000 description 24
- 108060000903 Beta-catenin Proteins 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 21
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 18
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- -1 BIO Chemical compound 0.000 description 15
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 14
- 108010067306 Fibronectins Proteins 0.000 description 14
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 102100037362 Fibronectin Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 12
- 230000002500 effect on skin Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 230000002269 spontaneous effect Effects 0.000 description 12
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 11
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000002356 single layer Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000010009 beating Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 9
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 7
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 102100022748 Wilms tumor protein Human genes 0.000 description 7
- 101710127857 Wilms tumor protein Proteins 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000002304 esc Anatomy 0.000 description 7
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 7
- 108091008803 APLNR Proteins 0.000 description 6
- 102000016555 Apelin receptors Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 238000003559 RNA-seq method Methods 0.000 description 6
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 6
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- PQXINDBPUDNMPE-UHFFFAOYSA-N 5-(furan-2-yl)-n-(3-imidazol-1-ylpropyl)-1,2-oxazole-3-carboxamide Chemical compound C1=C(C=2OC=CC=2)ON=C1C(=O)NCCCN1C=CN=C1 PQXINDBPUDNMPE-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 4
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 4
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 4
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 4
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 4
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 4
- HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 229950006240 hydrocortisone succinate Drugs 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- NTSBZVCEIVPKBJ-UHFFFAOYSA-N 1-azakenpaullone Chemical compound C1C(=O)NC2=CC=CN=C2C2=C1C1=CC(Br)=CC=C1N2 NTSBZVCEIVPKBJ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 3
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 3
- 101000702691 Homo sapiens Zinc finger protein SNAI1 Proteins 0.000 description 3
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 3
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 3
- 102100030917 Zinc finger protein SNAI1 Human genes 0.000 description 3
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 101150003286 gata4 gene Proteins 0.000 description 3
- 230000009067 heart development Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- OXPHUHSZLODPNL-UHFFFAOYSA-N 3,4-bis(1h-indol-7-yl)pyrrole-2,5-dione Chemical compound C=1C=CC=2C=CNC=2C=1C=1C(=O)NC(=O)C=1C1=CC=CC2=C1NC=C2 OXPHUHSZLODPNL-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001095308 Homo sapiens Periostin Proteins 0.000 description 2
- 101000800546 Homo sapiens Transcription factor 21 Proteins 0.000 description 2
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 2
- 102100037765 Periostin Human genes 0.000 description 2
- 241000179028 Peromyscus sejugis Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100023087 Protein S100-A4 Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100033121 Transcription factor 21 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- AJDONJVWDSZZQF-UHFFFAOYSA-N 1-(2,4,4-trimethylpentan-2-yl)-4-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]benzene Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 AJDONJVWDSZZQF-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010077596 Axin Signaling Complex Proteins 0.000 description 1
- 102000010264 Axin Signaling Complex Human genes 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 description 1
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 101150062301 Ddr2 gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100023855 Heart- and neural crest derivatives-expressed protein 1 Human genes 0.000 description 1
- 102100038654 Heart- and neural crest derivatives-expressed protein 2 Human genes 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000793362 Homo sapiens Apelin receptor Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101000905239 Homo sapiens Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- 101001031594 Homo sapiens Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 1
- 101000629402 Homo sapiens Mesoderm posterior protein 1 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101001032038 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Proteins 0.000 description 1
- 101000588969 Homo sapiens Putative uncharacterized protein MYH16 Proteins 0.000 description 1
- 101000653635 Homo sapiens T-box transcription factor TBX18 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108091006975 Iron transporters Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102100026822 Mesoderm posterior protein 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100038718 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102100032974 Putative uncharacterized protein MYH16 Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102220590686 Receptor-type tyrosine-protein phosphatase S_R96A_mutation Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 108010014480 T-box transcription factor 5 Proteins 0.000 description 1
- 102100036771 T-box transcription factor TBX1 Human genes 0.000 description 1
- 101710167705 T-box transcription factor TBX1 Proteins 0.000 description 1
- 102100029848 T-box transcription factor TBX18 Human genes 0.000 description 1
- 102100024755 T-box transcription factor TBX5 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- DLVAMZWIILNQTD-IEKAXWOWSA-H [O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.[O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.[O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.O.O.[Mg+2].[Mg+2].[Mg+2] Chemical compound [O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.[O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.[O-]P([O-])(OC(C(O[C@@H]1[C@H](CO)O)=O)=C1O)=O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.OC[C@@H]([C@H](C(O)=C1OP(O)(O)=O)OC1=O)O.O.O.[Mg+2].[Mg+2].[Mg+2] DLVAMZWIILNQTD-IEKAXWOWSA-H 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001625 cardiomyogenic effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 210000004060 endocardial cushion Anatomy 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 102000022382 heparin binding proteins Human genes 0.000 description 1
- 108091012216 heparin binding proteins Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000047215 human APLNR Human genes 0.000 description 1
- 102000056097 human CTNNB1 Human genes 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- 102000046661 human PECAM1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000001316 polygonal cell Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001811 primitive streak Anatomy 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 102220198146 rs1057519886 Human genes 0.000 description 1
- 102200044883 rs121913228 Human genes 0.000 description 1
- 102220198042 rs121913407 Human genes 0.000 description 1
- 102200044888 rs121913412 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- test agents may be characterized as having cardiac toxicity when the test agent modulates the functional parameter away from physiologically acceptable conditions.
- test agents may be screened for their influence on the prolongation of the QT interval, wherein test agents that prolong the QT interval will be considered agents with the potential to induce drug-induced long QT syndrome.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Methods for generating high-yield high-purity cardiac fibroblasts are described. Differentiation methods comprising thematically defined culture conditions and methods for in vitro maintenance of human pluripotent stern cell-derived cardiac fibroblasts are also provided.
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 62/402,694, filed Sep. 30, 2016, which is incorporated by reference in its entirety.
- This invention was made with government support under HL099773 and HIL129798 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The heart is comprised of multiple types of cells including cardiomyocytes, fibroblasts, endothelial cells, and vascular smooth muscle cells. Although cardiomyocytes occupy about 70% of the heart by volume, by cell number, non-myocytes are the majority of cells in the myocardium (Vliegen et al., European Heart J., 1991). Non-myocytes include cardiac fibroblasts (CFs), endothelial cells, and smooth muscle cells as well as circulating cells present in the heart. Previous studies have shown that CFs constitute either the most common or second most common non-myocyte cell type in mammalian hearts depending on the methodology used and species studied (Anversa et al., J. Molecular Cell. Cardiology 12(8): 781-795, 1980; Nag, Tissue & Cell 12(1):125-139, 1980: Banerjee et al., Am. J. Physiol.-Heart and Circulatory Physiology 293(3):H1883 -H1891, 2007; Bergmann et al, Cell 161(7):1566-1575, 2015; Pinto et al., Circ. Res. 118(3) 2016).
- Early activation of the cardiomyogenic transcriptional program in anterior lateral splanchnic mesoderm is mediated by positive and negative signals from adjacent endoderm, overlying ectoderm, and midline structures, including bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and canonical and noncanonical Wnt signaling (Evans et al., 2010). As the cardiac crescent and linear heart tube form, second heart field (SHE) cells in medial splanchnic mesoderm remain in contact with pharyngeal endoderm and their continued proliferation and delayed differentiation is regulated by canonical Wnt FGF, and Hedgehog. (Hh) signaling pathways (Kelly R G, Curr Topics Dev Biol 100:33-65, 2012). The roles of these signaling pathways have been dissected using experimental manipulation in avian embryos and conditional mutagenesis in the mouse, which show that Wnt/β-catenin signaling plays an upstream role in. promoting proliferation of SHF cells in vivo, and FGF ligands expression is downstream of canonical Wnt signaling (Cohen et 2007; Lin et al., 2007). FGF8 is thought to be the major FGF ligand driving SHF proliferation in vivo, with important contributions from FGF10 and FGF3 as revealed by analysis of compound mutant embryos (Eagan et al., 2006; Park et al., 2006, 2008; Urness et al., 2011; Watanabe et al., 2010).
- Although the CFs are not as well studied as cardiomyocytes, investigations over the last two decades have demonstrated multiple important roles of CFs in cardiac development, homeostasis, and response to injury (Lajiness & Conway, 2012). CFs are best known for generating the extracellular matrix that helps form the heart and regulate its function. For example, CFs are known to secrete collagen I and Ill abundantly as well as fibronectin and various proteoglycans. A second major function of CFs is the secretion of cytokines and growth factors. During development, signaling from CFs is necessary to stimulate myocyte growth and cell division as well as to dynamically remodel the extracellular matrix (leda el al, 2009). CFs play a central role in many forms of heart disease. In cardiac hypertrophy, which is the most significant risk factor for cardiac events and cardiac death, CFs contribute abnormal matrix synthesis. CFs also are intimately involved in many of the well-known signaling pathways linked to heart disease. For example, f3-adrenergic receptors are present on CFs, and the beneficial impact of β-adrenergic blockers in disease states such as heart failure likely are in part due to effects on CFs (D'Souza et al., 2011). Following a myocardial infarction or other form of inflammation or stress impacting the myocardium, CFs can become activated, generating myofibroblasts which produce the pathological fibrosis which is a major contributeo to organ dysfunction. Increased numbers of cardiac fibroblasts and fibrosis also lead to abnormal electrical conduction and increased risks for arrhythmias and sudden cardiac death (Kohl & Gourdi.e, 2014), Furthermore, while fibroblasts have been regarded as a common mesenchymal cell present in most tissues, distinct gene expression patterns and characteristics are beginning to define tissue-specific fibroblasts. For example, CFs have been demonstrated to express cardiac-specific genes highlighted by the expression of the transcription factors GATA4 and Tbx20 (Furtado et at., 2014).
- Human CFs hold promise for a variety of applications. Although cardiac cell therapy is actively being investigated by many groups around the world, clinically tested cell preparations have proven disappointing. CFs can be obtained from animal hearts for research, but human-specific biology is most accurately reflected by human CFs. Primary, viable human CFs are difficult to obtain from human cardiac samples obtained by heart biopsies, cardiac surgery, or at autopsy. In addition, primary CFs can be passaged only a limited number of times before senescence. Thus a robust and reliable source of human. CFs is needed for cardiovascular research and therapeutic applications. Accordingly, there is a need in the art for efficient and cost-effective protocols for generating functional cardiac fibroblasts under chemically defined culture conditions and in the absence of certain growth factors previously thought to be an essential part of directed cardiac fibroblast differentiation.
- The invention relates generally to methods for generating functional cardiac fibroblasts from hPSCs populations under chemically-defined conditions and for long-term maintenance of such hPSC-derived cardiac fibroblast cell populations.
- In a first aspect, provided herein is a method for generating a population of cardiac fibroblast cells, the method comprising: culturing human cardiac mesoderm progenitor cells in a chemically defined culture medium comprising a fibroblast growth factor, whereby a cell population comprising, human cardiac fibroblast cells is obtained after about 20 days in culture. The fibroblast growth factor can be bFGF/FGF2. At least 90% of cells in the cell population can be cardiac fibroblast cells positive for expression of one or more markers selected from the group consisting of GATA4, HAND2, ISLA, NICX2-5, SOX17BMP4, and WTI. In some cases, no cell separation or selection step is used to obtain the cell population comprising cardiac fibroblasts. The cardiac fibroblast cells can be capable of undergoing at least 10 cell divisions. The human cardiac mesoderm progenitor cells can be obtained from a method comprising culturing human pluripotent stem cells cultured in a chemically defined culture medium comprising an activator of Wnt/β-catenin signaling for about 2 to about 3 days, whereby a cell population comprising cardiac mesodermal cells positive for expression of Brachyury/T. The activator of Mint/β-catenin signaling can be a Gsk3 inhibitor. The Gsk3 inhibitor can be a small molecule selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide. The Gsk3 inhibitor can be CHIR99021 present in a concentration of about 0.2 μM to about 20 μM. The Gsk3 inhibitor can be CHIR99021 present in a concentration of about 12 μM.
- In a second aspect, provided herein is a method for generating a human arrhythmia model, the method comprising the steps of co-culturing a population of cardiac fibroblast cells in the presence of a population of cardiomyocytes in a chemically defined culture medium. The cardiac fibroblast cells can be generated by a method comprising culturing human cardiac mesoderm progenitor cells in a chemically defined culture medium comprising a fibroblast growth factor, whereby a cell population comprising human cardiac fibroblast cells is obtained after about 20 days in culture. The co-culture can include 10%, 50%, 70%, or 90% cardiac fibroblast cells. The co-culture can be seeded at a density between about 60,000 celislem2 and about 120,000 cells/cm2.
- In a third aspect, provided herein is a method of screening a test agent, the method comprising: co-culturing a population of cardiac fibroblast cells in the presence of a population of cardiomyocytes in a chemically defined culture medium; contacting the co-culture with a test agent; measuring a functional parameter of the contacted co-culture; and comparing the functional parameter to that parameter measured in a co-culture which has not been contacted with the test agent, wherein modulation of the functional parameter after contact. with the test agent indicates the test agent is a candidate therapeutic agent. The test agent can be selected from the group consisting of (i) an organic compound; (ii) a nucleic acid; (iii) a peptide; (iii) a polypeptide, and (iv) an antibody. The functional parameter can be selected from the group consisting of electrical impulse propagation pattern, conduction velocity, and action potential. duration. The electrical impulse propagation pattern can be measured using a fluorescent membrane potential dye. Acceleration of the conduction velocity after contact with the test agent can indicate the test. agent is a candidate therapeutic agent. Prolongation of the action potential duration after contact with the test agent can indicate the test agent is a candidate therapeutic agent. The electrical impulse propagation pattern can be measured as the fibrillatory or reentry pattern and an increase in the pattern after contact with the test agent indicates the test agent is a candidate therapeutic agent. The cardiac fibroblast cells can be generated by a method comprising culturing human cardiac mesoderm progenitor cells in a chemically defined culture medium comprising a fibroblast growth factor, whereby a cell population comprising human cardiac fibroblast cells is obtained after about 20 days in culture.
- In a fourth aspect, provided herein is a chemically defined culture medium comprising: a fibroblast growth factor, glutamine, ascorbic acid, hydrocortisone hemisuccinate, insulin, and DMEM. The glutamine can be provided as GlutaMAX. The medium can additionally comprise human serum albumin, linoleic acid, and lecithin. The medium is xeno-free.
- In a fifth aspect, provided herein is a kit for differentiating human pluripotent stem cells into cardiac fibroblasts, the kit comprising: (i) a chemically defined culture medium suitable for differentiating human cardiac progenitor cells into cardiac fibroblasts; (ii) an agent that activates Wnt signaling in human cardiac progenitor cells; (iii) a fibroblast growth factor; and (iv) instructions describing a method for generating human CFs, the method employing the culture medium, the agent, and the fibroblast growth factor. The chemically defined culture medium of (i) can comprise a fibroblast growth factor, GlutaMAX, ascorbic acid, hydrocortisone hemisuccinate, insulin, and DMEM. The agent that actives Wnt signaling can be a Gsk3 inhibitor. The Gsk3 inhibitor can be a small molecule selected from the group consisting of CHIR99021, CHIR.98014, BIO-acetoxime, BIO, LiCl SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylinaleimide,
- These and other features, objects,. and advantages of the present invention will become better understood from the description that follows. In the description, reference is made to the accompanying drawings, which form. a part hereof and in which there is shown by way of illustration, not limitation, embodiments of the invention. The description of preferred embodiments is not intended to limit the invention to cover all modifications, equivalents and alternatives. Reference should therefore be made to the claims recited herein for interpreting the scope of the invention.
- The patent or application file contains at least one drawing executed m color Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
- The present invention will be better understood and features, aspects and advantages other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such detailed description makes reference to the following drawings, wherein:
-
FIGS. 1A-1F demonstrate derivation of cardiac fibroblasts from stage-specific progenitors from human pluripotent stem cells (hPSCs). (FIG. 1A ) Schematic method of the cardiomyocyte differentiation protocol (“GiWi protocol”) and markers for stage-specific progenitors. (FIG. 1B ) Flow cytometric analysis of stage-specific progenitors generated in early differentiation (day 0-5) in the GiWi protocol from iPSC line 19-9-11 (FIG. 1C ) Schematic method for cardiac fibroblast differentiation induced by bFGF at the stage-specific progenitors. (FIG. 1D ) Flow cytometric analysis demonstrates changes in the abundance of cardiac fibroblast populations based on timing of bFGF/FGF2 exposure and dose. (FIG. 1E ) Average percentage of fibroblast population differentiated from hPSC lines at 20 days. CFBM, cardiac fibroblast basal medium (Table 1); MF 2O, antibody for sarcomere .myosin (Table 2); Fibroblast, antibody for fibroblast (Table 2). (FIG. 1F ) Stage-specific progenitors induced by bFGF signaling in cardiac fibroblast differentiation (red). -
FIGS. 2A-2C demonstrate gene expression characterization of SHF progenitors and cardiac fibroblasts in the GiFGF protocol. (FIG. 2A ) Schematic method of the GiFGF protocol and stage-specific progenitors in differentiation of hPSCs to cardiac fibroblasts (FIG. 2B ) qRT-PCR showing the transcription factors expression and hierarchy in the time course of the GiFGF protocol (day 0-20). (FIG. 2C ) qRT-PCR showing expression of markers for fibroblasts, cardiomyocytes and nonmyocyte lineages in the time course of the GiFGF protocol (day 0-20), MIP, mesodermal progenitor; CHIP, cardiac mesodermal progenitor; SHFP, second heart field progenitor; CF, cardiac fibroblast -
FIGS. 3A-3G demonstrates characterization of cardiac fibroblasts differentiated from human pluripotent stem cells (hPSC-CF) in comparison with primary cardiac fibroblast and dermal fibroblast. (FIG. 3A ) Morphology of hPSC-CF (iPSC line DF19-9-11T derived CF), primary cardiac fibroblast (NHCF-V) and human dermal fibroblast (hDF). (FIG. 3B ) Growth capacity of hPSC-CF and NHCF-V during passaging. (FIG. 3C ) CD90 expression by flow cytometry in hPSC-CF, NHCF-V and hDF during passaging. (FIG. 3D ) The fibroblast marker (clone TE-7) expression by flow cytometry in hPSC-CF, NHCF-V and hDF during passaging. (FIG. 3E ) Markers expression for endothelial cells (CD31), smooth muscle cells (SM-MHC) and cardiomyocytes (MF20) examined by flow cytometry in the 20 day hPSC-differentiated Cels by GiWi protocol, and CFs by GiFGF protocol and the CFs atpassage 5. (FIGS. 3F-3G ) Immunolabeling by antibodies for fibroblast (clone TE-7), cTnT, Gata4 (FIG. 3F ), and fspl, collagen I and fibronectin (FIG. 3G ) in hPSC-CF, NECF-V and hDF showing Gata4 only expressed in cardiac fibroblasts, not in dermal fibroblasts, while fibroblast, fsp1, collagen I, and fibronectin expressed in all fibroblasts -
FIGS. 4A-4F demonstrate gene expression characterization of hPSC-CF, comparison with NHCF-V hDF, hPSC-CM and hPSC by RNA-sect, and the 3D structure of ECM scaffolds from hPSC-CF, NHCF-V and hDF. (FIG. 4A ) Dendrogram of similarity in the abundance of overall transcripts (19,084 genes) across samples of hPSC-CFs, NHCF-V, hDF, hPSC-CM and hPSC and calculated by Euclidean distance. (FIG. 4B ) Heatmap of cardiac factors (57 genes) expression across samples of hPSC-CFs, NHCF-V, hDF, hPSC and hPSC-CM. (FIG. 4C ) Fleatmap of extracellular matrix related gene expression (98 genes) across samples of hPSC-CFs, NHCF -V, hDF, hPSC and hPSC-CM. (FIG. 4D ) Confocal z-scan images of collagen I and fibronectin immunolabeling showing the 3D reconstruction of collagen and fibronectin extracellular matrix relative to the cells in the high density culture of hPSC-CF, NHCF-V and hDF. (FIG. 4E ) Thickness of the 3D ECM scaffolds of hPSC-CF, NHCF-V and hDF. *P<0.05, one-way ANOVA with post-hoc tests. (FIG. 4F ) Relative expression of cardiac factors BMP4, GATA4, HAND2, HETY1, ISL1, NKX2-5, SOX17 and WT1 (fold change normalized to GAPDH) in hPSC-CFs, NHCF-V, hDF, hPSC, and hPSC-CM. -
FIG. 5 presents flow cytometric analysis of stage specific progenitor cells in differentiation of human pluripotent stem cell line H1 at day 0-5 using the GiWi protocol. Images show cell surface expression of different progenitor stages. Colored boxes demonstrate pattern of gene expression in progenitors derived from H1 cell line. Green box: Brachyury positive early mesoderm. Red box: Brachyury low, CD90+. Purple box: APLNR+. Orange box: PDGFR-alpha/KDR positive progenitors: -
FIG. 6 presents quantitative RT-PCR of transcription factors in the time course (day 0-20) of cardiac fibroblast differentiation using the GiFGF protocol. Relative expression of each gene normalized to GAPDH is plotted. -
FIGS. 7A-7C show gene expression characterization in the cardiac fibroblast differentiation protocol GiFGF, compared with the cardiomyocyte differentiation protocol-GiWi by qRT-PCR (FIG. 7A ) VHF and SHF specific gene expression in the GiFGF and GiWi protocols. (FIG. 7B ) Gene expression pattern in GiFGF and GiWi protocols (day 0-20). (FIG. 7C ) Relative gene expression (normalized to GAPDH) by quantitative RT-PCR of transcription factors of EMT (Epithelial to Mesenchymal Transition) in the time course of cardiac fibroblast differentiation using the GiFGF protocol. -
FIG. 8 presents flow cytometric analysis by histogram of CD90 expression in culture of human primary CF (NHCF-V), human iPSC differentiated CF (19-9-11p46 CF), H1p51 CF, human ESC differentiated CF (TnnT2p47 CF) and human primary dermal fibroblast (hDF (020a)) during passaging. P indicates passage. TnnT2 is a transgenic hES cell line from H9 containing the human cardiac specific troponin (TNNT2) promoter driving expression of copGFP, the full name is H9-cTnT-GFP (Wrighton P J et al. PNAS 2014). -
FIG. 9 presents flow cytometric analysis by dot plot of MF20 (anti-sarcomere myosin) and fibroblast done TE-7, anti-human fibroblast) expression in culture of human primary CF (NHCF-V), human iPSC differentiated CF (19-9-11p46 CF), human ESC differentiated CF (TnnT2p47 CF) and human primary dermal fibroblast (hDF (020a)) during passaging. P indicates passage. -
FIGS. 10A-10D show co-culture of hPSC-CMs with either hPSC-CFs or hDFs. (FIG. 10A ) confocal images showing the ratios of hPSC-CMs co-cultured with hPSC-CFs for use in functional experiments. (FIG. 10B ) Time-space plots of optical mapping experiments. Post acquisition analysis of optical recordings was done by plotting the changes of fluorescence over time over a single line of each monolayer-similar to a confocal line scan. Each spontaneous activation is represented by a flash of light which propagated over the entire monolayer shown in these 5 s recordings. (FIG. 10C ) Quantification of spontaneous beating rate (Hz) and action potential propagation velocity (cm/s). Beating rate of 100% CM monolayers was 2,2±0.09 Hz 10% hPSC-CFs increased beating rate frequency to 2.4±0.05 Hz 50% hPSC-CFs resulted in average beating rate of 1.9±0.06 Hz. hPSC-CFs did not significantly change the spontaneous beating rate of these monolayers. On the other hand, 10% hDF significantly reduced the beating rate to 0.93±0.03 Hz (*P=2.6×10-7) and 50% hDF reduced the beating rate to 0.7±0.04 Hz (#P=7.0×10-8); unpaired t-test each compared to 100%CM monolayers. Conduction velocity of 100% CM monolayers was 25.2±2.4 cm/s. 10% hPSC-CFs reduced velocity to 11.1±0.34 cm/s and hDFs reduced conduction velocity to a greater extent, to 5.7±0.27 cm/s. 50% hPSC-CFs caused fibrillatory conduction which precluded quantification of impulse propagation velocity and 50% hDFs further reduced conduction velocity to 2.6±0.14 cm/s. Comparisons with 100% CM monolayers: **P=1.1×10−4; #P=7.9×10−6; †P=2.5×10−6; unpaired t-tests. (FIG. 10D ) APD80 restitution curves show that hDFs have distinct effect on cardiac monolayer compared to hPSC-CFs. Data shown for 10% hDF or hPSC-CF co-culture condition. -
FIG. 11 shows flow cytometry of cells labeled with ISL1 and CXCR4 antibodies at progenitor stages in the differentiation into cardiac fibroblasts using the GiFGF protocol and differentiation into cardiomyocytes using the GiWi protocol as a comparison. - While the present invention is susceptible to various modifications and alternative forms, exemplary embodiments thereof are shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description of exemplary embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
- publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though set forth in their entirety in the present application.
- The methods and compositions provided herein are based at least in part on the Inventors' discovery that differentiation stage-specific modulation of canonical Wnt signaling and FGF signaling is sufficient to efficiently obtain cardiac fibroblasts from human pluripotent stem cells (hPSCs) under chemically defined conditions. Activation of Wnt signaling induces mesodermal differentiation, while subsequent Wnt inhibition drives cardiac specification. Exposure to active FGF signaling in cardiac progenitors specifies SHF progenitor cells and cardiac fibroblasts (CFs). Human PSC-derived CFs retain many characteristics of primary CFs, including, expression of biomarkers including GATA4, HAND2, HEY1, ISL1, NKX2-5, SOX17, BMP4, and WT1. The biomarkers GATA4, HAND2, HEY1, ISL1, NKX2-5, SOX17, BMP4 , and WT1 show higher expression in hPSC-CFs than in primary CFs and the cytokine IL-6 shows reduced expression in hPSC-CFs. The chemically defined platform described here should be widely useful for generating functional cardiac fibroblasts for both research and clinical applications.
- The CF differentiation process provided herein is chemically defined, and generates CFs from human pluripotent stem cells at a greater yield and lower cost than existing methods. In addition, these cells are suitable for translational applications since they can be derived in the absence of xenogeneic components. Since access to primary human CFs is limited by the scarcity of viable cardiac tissue, the methods provided herein have valuable applications such as inexpensive and reproducible generation of human CFs. Generating human CFs in chemically-defined conditions can facilitate translation of these cells to regenerative therapies and other clinical applications. As described in further detail below, the Inventors' protocols targeted. key regulatory elements of the Wnt/β-catenin and FGF signaling pathways, simplifying the steps and components involved in deriving second heart field progenitors from pluripotent stem cells and deriving cardiac fibroblasts from the second heart field progenitors.
- As used herein, the term “cardiac fibroblast” (“CF”) refers to cells of the cardiac fibroblast lineage obtained in vitro according to a method provided herein. Cardiac fibroblasts are characterized and identified by expression of biomarkers including the transcription factors GATA4 (GATA Binding Protein 4) and HAND2 (“Heart And Neural Crest Derivatives Expressed 2”). GATA4 encodes a member of the GATA family of zinc-finger transcription factors. The GATA4 gene product plays a key role in cardiac development. As used herein, the term “biomarker” or “marker” refers to a biomolecule (e.g., protein, nucleic acid, carbohydrate, or lipid) that is differentially expressed in a cell in comparison to another cell type. Generally, biomarkers can be identified by, for example, gene expression analysis, including quantitative PCR, RT-PCR, RNA-Seq, Northern analysis, and in snit hybridization.
- As used herein, the term “second heart field (SHF) progenitors” refers to cardiac progenitor cells obtained in vitro according to a method provided herein and that exhibit at least some properties of primary second heart field progenitors. SHF progenitors give rise to myocardium, smooth muscle, and endothelial cells, and can be identified based on expression of biomarkers such as TBX1 (also known as T-
Box 1 and Brachyury), HAND2, andFGF 10. In vivo, SHF progenitors are believed to be pharyngeal mesodermal progenitor cells that are situated medially to the primary or first heart field (FHF). While FHF progenitors contribute to the left ventricle, SHF progenitors contribute to the cardiac outflow tract (OFT), right ventricle, and inflow tract. During embryonic development, SHF progenitors contribute to growth of the elongating heart tube during looping morphogenesis. See, for review, Rochais et al., Circ. Res. 104:933-942 (2009). - In a first aspect, provided herein is a method for generating a population of human cardiac fibroblasts, where the method generally comprises culturing human pluripotent stem cells under conditions that promote differentiation of the hPSCs into second heart field progenitors and, ultimately, cardiac fibroblasts. As used herein, the phrases “differentiation into human cardiac fibroblast cells” and “differentiating into human cardiac fibroblast cells” refer to promoting the differentiation of iPS cells or human cardiac mesoderm progenitor cells into cells exhibiting the genetic markers, biomarkers cell function, and/or cell morphology characteristic. of a human cardiac fibroblast cell.
- Preferably, the method comprises culturing human cardiac mesoderm progenitor cells in a chemically defined, also preferably yet optionally, xeno-free culture medium including a fibroblast growth factor (FG.F), whereby a cell population including human cardiac fibroblast cells is obtained after about 16-24 days in culture (i.e., about 16, 17, 18. 19, 20, 21, 22, 23, or 24 days in culture). In one embodiment, the human cardiac mesoderm progenitor cells are cultured for 20 days.
- As used herein, the term “fibroblast growth factor” or “FGF” refers to members of a family of growth factors involved in angiogenesis, wound healing, and embryonic development. FGFs are heparin-binding proteins and interactions with cell-surface-associated. heparan sulfate proteoglycans have been shown to be essential for FGF signal transduction. FGFs are key players in the processes of proliferation and differentiation of wide variety of cells and tissues. There are several different FGF subfamilies, the member ligands of which include FCF1-FGF23. Of the known FGF ligands, all show some degree of overlap of receptor binding, with the exception of FGF11-FGF14.
- In some embodiments, the FGF is selected from the group consisting of bFGF/FGF2, FGF4, FGF8, FGF10 and the mixtures thereof. While FGF2 has been primarily used in this stage, other factors, including FGF4, FGF8 or FGF10 can be used in place of FGF2. One may also use mixtures of two or more of FGF2, FGF4, FGF8 and FGF10 in this stage. In a specific embodiment, the FGF is FGF2.
- In some embodiments, the effective concentration of FGF in the medium ranges from about 10 ng/ml to about 200 ng/ml. For example, the effective concentration of FGF may range from about 10 ng/ml to about 200 ng/ml, or from about 20 ng/ml to about 180 ng/ml, or about 30 ng/ml to about 170 ng/ml, or about 40 ng/ml to about 160 ng/ml, or about 50 ng/ml, to about 150 ng/ml, or about 60 ng/ml to about 140 ng/ml, or about 70 ng/ml to about 130 ng/ml, or about 80 ng/ml to about 120 ng/ml. Preferably, the effective concentration of FGF ranges from about 25 ng/ml to about 125 ng/ml. More preferably, the effective concentration of FGF is about 75 ng/ml.
- In some cases, the human cardiac mesoderm progenitor cells are obtained from a method involving culturing human pluripotent stem cells for about 2 to about 3 days in a chemically defined, albumin-free culture medium including an activator of Wnt/β-catenin signaling, whereby a cell population including cardiac mesodermal cells positive for expression of Brachyury/T is obtained.
- As described herein, cells of the CF lineage can be generated without providing exogenous TGFβ superfamily growth factors such as Bone Morphogenetic Protein 4 (BMP4) and without generating epicardial cells as an intermediate cell type.
- As will be appreciated by those of ordinary skill in the art, Wnt/β-catenin signaling can be activated by modulating the function of one or more proteins that participate in the Wnt/β-catenin signaling pathway to increase β-catenin expression levels or activity, TCF and LEF expression levels, or β-catenin/TCF/LEF induced transcriptional activity.
- in some embodiments, Wnt/β-catenin signaling is activated by inhibiting Gsk3 phosphotransfaase activity or Gsk.3 binding interactions. While not wishing to be bound by theory, it is believed that inhibition of Gsk3 phosphorylation of β-catenin inhibits tonic degradation of β-catenin and thereby increases the β-catenin level and activity to drive pluripotent stem cell differentiation to an endodermallmesodermal lineage. Gsk3 inhibition can be achieved in a variety of ways including, but not limited to, providing small molecules that inhibit Gsk3 phosphotransferase activity, RNA interference knockdown of Gsk3, and overexpression of dominant negative forms of Gsk3. Dominant negative forms of Gsk3 are known in the art as described, e.g., in Hagen et al. (2002), 0i J Biol Chem, 277(26):23330-23335, which describes a Gsk3 including a R96A mutation.
- In some embodiments, Gsk3 is inhibited by contacting a cell with a small molecule that inhibits Gsk3 phosphotransferase activity or Gsk3 binding interactions. Suitable small molecule Gsk3 inhibitors include, but are not limited to, CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB 216763, SB 415286, AR A014418, 1-Azakenpaullone, Bis-7-indolylmaleimide, and any combinations thereof. In some embodiments, any of CHIR99021, CHIR98014, and BIO-acetoxime are used to inhibit Gsk3 in pluripotent stem cells in the differentiation methods described herein, in one embodiment, the small molecule Gsk3 inhibitor is CHIR99021 at a concentration ranging from about 0.2 μM to about 20 μM, e.g., about 0.2 μM 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, 1 μM, 2 μM, 3 μM, 4 μm, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, 10 μM, 12 μM, 15 μM, 18 μM, 20 μM or another concentration of CHIR99021 from about 3 μM to about 20 μM. In another embodiment, the small molecule Gsk3 inhibitor to be used is CHIR98014 at a concentration ranging from about 0.1 μM to about 1 μM, e.g., about 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM or another concentration of CHIR98014 from about 0.1 μM to about 1 μM. In another embodiment, the small molecule Gsk3 inhibitor is BIO-acetoxime at a concentration ranging from about 0.1 μM to about 1 μM, e.g., about 0.1 μM, 0.2 μM, 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM or another concentration of BIO-acetoxime from about 0.1 μM to about 1 μM.
- In other embodiments, Gsk3 activity is inhibited by RNA interference knockdown of Gsk3. For example, Gsk3 expression levels can be knocked-down using commercially available siRNAs against Gsk3, e.g., Signal Silence® GSK-3α/β siRNA (catalog #6301 from Cell Signaling Technology®, Danvers, Mass.), or a retroviral vector with an inducible expression cassette for Gsk3, e.g., a commercially available Tet-inducible retroviral RNA interference (RNAi) system from Clontech (Mountain View, Calif.) Catalog No. 630926, or a curate-inducible system from Systems Biosciences, Inc. (Mountain View, Calif.), e.g., the SparQ® system, catalog no. QM200PA-2.
- in other embodiments, the Wnt/β-catenin signaling pathway is activated by overexpressing β-catenin itself, e.g., human β-catenin (exemplary nucleotide and amino acid sequences are found at GenBank Accession Nos: X87838 and CAA61107.1, respectively). In one embodiment,p-catenin overexpression is achieved using an inducible expression system, e.g., any of the just-mentioned inducible expression systems. Alternatively, a constitutively active, stabilized isoform of β-catenin is used, which contains point mutations S33A, S37A, T41A, and S45A as described, ez., in Baba et al (2005), Immunity 23(6):599-609.
- In yet other embodiments, Wnt/β-catenin signaling pathway activation in pluripotent stem cells is achieved by contacting the cells with an agent that disrupts the interaction of -catenin with Axin, a member of the β-catenin destruction complex. Disruption of the Axin/β-catenin interaction allows β-catenin to escape degradation by the destruction complex thereby increasing the net level of β-catenin to drive β-catenin signaling. For example, the Axin/β-catenin interaction can be disrupted in pluripotent cells by contacting the cells with the compound 5-(Furan-2-yl)-N-(3-(1H-imidazol-1-yl)propyl)-1,2-oxazole-3-carboxamide (“SKL2001”), which is commercially available, e.g., as catalog no. 681667 from EMD Millipore. An effective concentration of SKL2001 to activate Wnt/β-catenin signaling ranges from about 10 μM to about 100 μM, about 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM or another concentration of SKL2001 from about 10 μM to about 100 μM.
- The methods provided herein produce populations of pluripotent stem cell-derived CFs, where the population is a substantially pure population of cardiac fibroblasts. As used herein, the term “substantially pure” refers to a population of cells that is at least about 75% (e.g., at least about 75%, 85%, 90%, 95%, 98%, 99o or more) pure, with respect to C,Fs making up a total cell population. In other words, the term “substantially pure” refers to a population of CFs of the present invention that contains fewer than about 20%, fewer than about 10%, or fewer than about 5% of non-cardiac fibroblast cells (e.g., cardiomyocytes) when directing dil:Threntiation to obtain cells of the CF lineage. The term “substantially pure” also refers to a population of CFs of the present invention that contains fewer than about 25%, about 10%, or about 5% of non-CFs in an isolated population prior to any enrichment, expansion step, or differentiation step. Typically, a population including CFs obtained by the disclosed methods comprises a very high proportion of CFs. In some embodiments, the cell population comprises about 50% to about 99% CFs, e.g., about 52%, 55%, 67%, 70%, 72%, 75%, 80%, 85%, 90%, 95%, 98%, or another percent of CFs from about 50% to about 99% CF's.
- Cardiac fibroblasts can be identified by the presence of one or more CF markers. Useful gene expression or protein markers for identifying CFs include, without limitation,
GA TA 4, HAND2, HEY1, ISL1, KNX2-5, and WT1 (Wilms tumor protein). Preferably, the method yields a cell population, at least 90% (e.g., at least 90%, 93%, 95%, 96%, 97%, 98%, 99% or more) of which are CFs positive for fibroblast marker (anti-human fibroblast antibody, clone TE-7. Millipore) and cardiac transcription factor GATM, and negative for cardiomyocytes markers including MF20, cTnT. Mdlecular markers of CFs can be detected at the mRNA expression level or protein level by standard methods in the art. some embodiments, no cell separation step or method is used to obtain a second cell population including at least 70% GATA4+ cells or at least 85% GATA4+ cells. In other embodiments, the proportion of CFs in a population of cells obtained in the described methods is enriched using a cell separation, cell sorting, or enrichment method, e.g., flow cytometry, fluorescence activated cell sorting (FACS), enzyme-linked immunosorbent assay (ELISA), magnetic. beads, magnetic activated cell sorting (MACS), laser-targeted ablation of non-CF cells, and combinations thereof. Preferably, flow cytometry or FACS is used to identify and separate cells based on cell-surface antigen expression. In some embodiments, certain CF functional criteria are also assessed. Such functional cardiac fibroblast. cell criteria include, without limitation, the ability to adhere and proliferate on tissue culture plastic (polystyrene) without coating, to migrate (for example, when assessed using a scratch assay), to generate cardiac-specific extracellular matrix proteins, and to form C×43 based gap junctions with cardiomyocytes. - Each culturing step of the methods described herein is preferably performed under chemically defined and, also preferably yet optionally, xeno-free conditions. Chemically defined culture medium and substrate conditions for culturing pluripotent stem cells, as used in the methods described herein, are well known in the art. As used herein, the terms “chemically-defined culture conditions” and “fully-defined conditions” indicate that the identity and quantity of each medium ingredient is known and the identity and quantity of supportive surface is known. For purposes of this disclosure, “xeno-free” means having no xenogeneic products of non-human animal origin, such as cells, tissues and/or body fluids, or any tissue or blood components, such as non-human serum, which contain variable and undefined factors. The use of xeno-free medium and culture substrates reduces the risk. of viral contamination or prion transmission. Accordingly, for human cells, a xeno-free culture medium is defined as a culture medium essentially free of non-human animal components.
- In exemplary embodiments human pluripotent stem cell-derived cardiac progenitor cells are singularized and replated at a low cell density in a basal culture medium. Optionally, such single cell replating is followed by a period of outgrowth before proceeding to activation of Wnt/β-catenin pathway signaling according to a method of generating CFs as provided herein.
- As used herein, “pluripotent stem cells” appropriate for use according to a method of the invention are cells having the capacity to differentiate into cells of all three germ layers. Pluripotent stem cells (PSCs) suitable for the differentiation methods disclosed herein include, but are not limited to, human embryonic stem cells (hESCs), human induced pluripotent stem cells (hiPSCs) non-human primate embryonic stein cells (nhpESCs), non-human primate induced pluripotent stem cells (nhpiPSCs). As used herein, “embryonic stem cells” or “ESCs” mean a pluripotent cell or population of pluripotent cells derived from an inner cell mass of a blastocyst. See Thomson et al. Science 282:1145-1147 (1998). These cells express Oct-4, SSEA-3, SSEA-4, TRA-1-60, and TRA4-81, and appear as compact colonies having a high nucleus to cytoplasm ratio and prominent nucledlus. ESCs are commercially available from sources such as WiCell Research Institute (Madison, Wis.).
- As used herein, “induced pluripotent stem cells” or “iPS cells” mean a pluripotent cell or population of pluripotent cells that may vary with respect to their differentiated somatic cell of origin, that may vary with respect to a specific set of potency-determining factors and that may vary with respect to culture conditions used to isolate them, but nonetheless are substantially genetically identical to their respective differentiated somatic cell of origin and display Characteristics similar to pluripotent stem cells, such as ESCs, as described herein. See, e.g., Yu ei al., Science 318:1917-1920 (2007). Induced pluripotent stem cells exhibit morphological properties (e.g., round shape, large nucleoli and scant cytoplasm) and growth properties (e.g., doubling time of about seventeen to eighteen hours) akin to ESCs. In addition, IPS cells express pluripotent cell-specific markers (e.g., Oct-4, SSEA-3, SSEA-4, Tra-1-60, or Tra-1-81, but not SSEA-1). Induced pluripotent stem cells, however, are not immediately derived from embryos. As used herein, “not immediately derived from embryos” means that the starting cell type for producing iPS cells is a non-embryonic, non-pluripotent cell, such as a multipotent cell or terminally differentiated cell, such as somatic cells obtained from a post-natal individual.
- Human iPS cells can be used according to a method described herein to obtain CFs having the genetic complement of a particular human subject. For example, it may be advantageous to obtain CFs that exhibit one or more specific phenotypes associated with or resulting from a particular disease or disorder of the particular mammalian subject. In such cases, iPS cells are obtained by reprogramming a somatic cell of a particular human subject according to methods known in the art. See, for example, Yu et al., Science 324(5928):797-801 (2009), Chen et al., Nat. Methods 8(5):424-9 (2011); Ebert et al., Nature 4:57(7227)277-80 (2009), Howden et al., Proc. Nail Acad. Sci. U.S.A. 1.08(16):6537-42 (2011). Induced pluripotent stem cell-derived CFs allow modeling of drug responses in CFs obtained from an individual having, for example, a particular disease. Even the safest drugs may cause adverse reactions in certain. individuals with a specific genetic background or environmental history. Accordingly, human subject-specific iPS cell-derived CFs are useful to identify genetic factors and epigenetic influences that contribute to variable drug responses.
- Subject-specific somatic cells for reprogramming into iPS cells can be obtained or isolated from a target tissue of interest by biopsy or other tissue sampling methods. in some cases, subject-specific cells are manipulated in vitro prior to use. For example, subject-specific cells can be expanded, differentiated, genetically modified, contacted to polypeptides, nucleic acids, or other factors, cryo-preserved, or otherwise modified.
- In some embodiments, pluripotent stem cells to be differentiated according to the methods disclosed herein are cultured in the presence of a serum-free, chemically-defined culture medium such as LaSR basal medium (a serum-free culture medium containing Advanced DMEM/F12, 2.5 mM GlutaMAX, and supplemented with 60 μg/mL ascorbic acid), mTESR-1®medium (StemCell Technologies, Inc., Vancouver, Calif.), or Essential 8 medium (life Technologies, Inc.). A number of known basal culture media are suitable for use throughout the differentiation methods described herein. Such basal culture media include, but are not limited to, RPMI, DMEM/F12 (1.:3), DMEM/F12 (1:3), DMEM/F12 (1:3), F12, DMEM, and MEM. In exemplary embodiments, these basal cell culture media are supplemented with 50 to 200 μg/ml L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (e.g., Sigma, catalog no. A8960). For each differentiation step described herein, cells are cultured in a medium that is substantially free of exogenous Bone Morphogenetic Proteins (BMPs) such as BMP4.
- In some cases, the basal culture medium is supplemented with suitable amounts of various components such as fatty acids or lipids, amino acids (such as non-essential amino acids), vitamin(s), growth factors, cytokines, antioxidant substances, 2-mercaptoethanol, pyruvic acid, buffering agents, inorganic salts, or serum such as fetal calf serum or autologous serum. Preferably, for being used in human therapy, the medium is serum-free, is supplemented with autologous serum, or contains an alternative to serum. From the aspect of preventing contamination with heterogeneous animal-derived components, serum can be derived from the same animal as that of the stem cell(s). Alternatives to serum can include materials which appropriately contain albumin (such as lipid-rich albumin, albumin substitutes such as recombinant albumin, plant starch, dextrans and protein hydrolysates), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3′-thiolglycerol, or equivalents thereto. The alternatives to serum can be prepared by the method disclosed in International Publication No. 98/30679, for example Alternatively, any commercially available materials can be used for more convenience. The commercially available materials include knockout Serum Replacement (KSR), Chemically-defined lipid concentrate (Gibco), and Glutamax (Gibco).
- In some cases, cells to be differentiated according to the methods disclosed herein are cultured in the presence of an extracellular matrix (ECM) substrate or a substrate including one or more ECM proteins. Examples of ECM protein that may be useful in a substrate for the methods provided herein include laminin, collagen I, collagen IV, fibronectin, and vitronectin, by themselves or in various combinations. The ECM proteins may be of natural origin and purified from human or animal tissues. Alternatively, the ECM proteins may be genetically engineered recombinant proteins or synthetic in nature. The ECM proteins may be a whole protein or in the form of peptide fragments, native or engineered. In some cases, pluripotent stem cells to be differentiated according to the methods disclosed herein are cultured in the presence of a commercial product such as a Synthemax™ cell culture surface (Corning) or Matrigel™. In such cases, substrate materials can be coated onto tissue culture treated flasks and multi well plates. In certain aspects, Matrigel™ may be excluded from the cell culture. Matrigel™ is a gelatinous protein mixture secreted by mouse tumor cells and is commercially available from .BD Biosciences (New Jersey, USA). In some embodiments, the pluripotent stem cells to be diMrentiated are cultured in the presence of an ECM substrate. In some embodiments, the human cardiac mesoderm progenitors are cultured in the presence of an ECM substrate. In some embodiments, the progenitors may be dissociated and replated on a solid substrate in the presence of Matrigal™.
- In a further aspect, provided herein are compositions and methods for expanding a self-renewing population of human. CFs for at least It) population doublings. Preferably, the self-renewing population of human CFs are capable of being passaged at least 10, 11, 12, or 13 times, wherein the cells are non-senescent and are not immortalized. Therefore, provided herein is an expandable source of functional human cardiac fibroblast cells.
- In a further aspect, provided herein is a co-culture generated using the cardiac fibroblast cells produced by the methods described herein. hPSC-CFs produced as described herein are co-cultured with hPSC-CMs to produce a model of cardiac functionality. The co-culture may comprise 100%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, 10% or 5% CMs with the balance of the total cell population in the co-culture including CF's (i.e., when the co-culture comprises 90% CMs, total cell population comprises 10% CTs). Co-cultures of the present invention are plated in chemically defined medium at a density sufficient to form a monolayer. In some embodiments, the co-culture is cultured for about 7 days (i.e., about 4, 5, 6, 7, 8, 9, or 10 days) in one embodiment, cells are plated at a density of about 250,000 cells per 200 μl drop of medium. In some embodiments, the cells are plated at a density between about 50,000 cells per 200 μl drop and about 500,000 cells per 200 μl. In some embodiments, the cells are plated at a density of between about 60,000 cells/cm2 and about 120,000 cells/cm2 (i.e., about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, about 110,000 or about 120,000 cells/cm). In some embodiments, the medium is EB20 (80% DMEM/F12, 0.1 mmol/L nonessential amino acids, 1 mmol/L 1-glutamine, 0.1 mmol/L β-mercaptoethanol, 20% FBS and 10 μmol/L blebbistatin), EB2 (RPMI plus 2% FBS), or RPMI (Invitrogen, Gibco) medium. In one embodiment, the medium is RPMI medium with B27 supplement. In some embodiments, the co-cultures are cultured in the presence of an extracellular matrix (ECM) substrate or a substrate including one or more ECM proteins.
- The co-culture generated by the methods described herein may be used to assess or evaluate a number of functional parameters known in the art, including but not limited to, beating rate frequency, action potential duration, action potential shape, action potential conduction velocity, conduction pattern (reentry, rotors. librillatory) (Campbell et al., 2012 Physiol, 590(24):6363-79; Hou et al., 2010 Circ Res., 107(12):1503-I I; Kleber et al., Physiol Rev. 2004, 84(2):431-88) , intracellular calcium cycling, contraction, and metabolic fluxes. Any means known in the art for measuring or observing these functional parameters may be used. In some embodiments, these functional characteristics are measured by optical mapping. In some embodiments, intracellular calcium cycling is measured using fluorescent dyes including but not limited to Fura2 and Fluo4. in some embodiments, contraction is measured by video edge detection or matrix bead displacement. In some embodiments, metabolic flux and metabolic properties of the co-culture are measured using the Seaborse assay system.
- The co-cultures of CFs and CMs described herein can be used to model cardiac arrhythmias by manipulating the ratio of CM to CF cells in the co-culture. In one embodiment, the co-culture comprises 10% hPSC-CFs and exhibits an increased beating rate frequency. In one embodiment, the co-culture comprises 50% hPCS-Cps and exhibits fibrillatory conduction. In some embodiments the co-cultures are used. to model spontaneous rate, electrical impulse conduction velocity and patterns of conduction. in some embodiments, the co-cultures are electrically paced to control their rate.
- In a further aspect, described herein are methods of using the CF and CM co-culture as a cardiac arrhythmia model to screen drug candidates for their efficacy inhibiting human cardiac arrhythmic behavior. In some embodiments,. a co-culture of cardiac fibroblasts. and cardiomyocytes are contacted with a test agent and the effect of the test agent on the co-culture is observed or measured. In some embodiments, cardiac fibroblast cells generated by the methods described herein are co-cultured with cardiomyocytes and labelled with a suitable fluorescent dye to quantify spontaneous electrical impulse propagation and other electrophysiological properties of the co-culture and the co-culture is contacted with a test agent. The co-culture may be contacted with the test agent for any amount of time. Following contact by the test agent, the spontaneous rate, electrical impulse conduction velocity and pattern of conduction as well as other electrophysiological properties (e.g., action potential duration) are measured and compared to the same properties measured in a co-culture which has not been contacted by the test agent. In some embodiments, the test agent may increase the impulse conduction velocity and/or increase the action potential duration to block the fibrillatory or reentry patterns of conduction indicating that the, test agent is a candidate agent suitable for the treatment of cardiac arrhythmia. Modulation of the functional parameter after contacting the co-culture with the test agent will indicate the test agent's utility as a candidate therapeutic agent for the treatment of a cardiac arrhythmia. in some embodiments, an increase in the functional parameter will indicate that the test agent is a candidate therapeutic agent. In some embodiments, a decrease in the functional parameter will indicate that the test agent is a candidate therapet agent. In embodiments wherein the co-cultures are electronically paced, the change in the functional parameter may be different than those observed in the same co-culture with a spontaneous rate.
- It is also envisioned that the co-cultures of the present invention may be used to screen for proarrhythmic effects of a test agent. In some embodiments, a test agent may be characterized as having cardiac toxicity when the test agent modulates the functional parameter away from physiologically acceptable conditions. In some embodiments, test agents may be screened for their influence on the prolongation of the QT interval, wherein test agents that prolong the QT interval will be considered agents with the potential to induce drug-induced long QT syndrome.
- As used herein, “test agent,” refers to a molecule assessed for its ability to alter a specific phenotypic endpoint. Examples of test agents include, but are not limited to, (i) organic compounds of molecular weight less than about 600 daltons; (ii) nucleic acids; (iii) peptides (including stapled peptides); (iii) polypeptides; and (iv) antibodies. In some embodiments, the test agent is a thug specifically targeted to cardiac fibroblast cells, cardiomyocytes, or both. In some embodiments, the test agent is a beta-adrenergic receptor blocker. In some embodiments, beta-adrenergic receptor blockers which can target receptors on both cardiac fibroblasts and carchomyocytes will be tested to determine the antiarrhythmic efficacy.
- Articles of Manufacture
- In another aspect, provided herein is a chemically defined culture medium for the differentiation of human cardiac progenitors into CFs. The culture medium comprises (i) a fibroblast growth factor; (ii) glutamine, provided as L-glutamine or GlutaMAX; (iii) ascorbic acid; (iv) hydrocortisone hemisuccinate; (v) insulin; (vi) human serum albumin; (vii) linoleic acid; (viii) lecithin; and (ix) DMEM, high glucose. In some embodiments, the medium is xeno-free. In some embodiments, glutamine is provided as GlutaMAX.
- In another aspect, provided herein is a kit for generating human CFs. In exemplary embodiments, the kit comprises (i) a culture medium suitable for differentiating human cardiac progenitor cells into CFs; (ii) an agent that activates Wnt signaling in human cardiac progenitor cells; (iii) a fibroblast growth factor; and (iv) instructions describing a method for generating human CFs, the method employing the culture medium, the agent, and the fibroblast growth factor. in some cases, a kit provided herein further comprises or alternatively comprises instructions describing methods for in vitro maintenance of human CFs obtained according to a method provided herein, where the method employs a culture medium suitable for maintaining human CFs and an agent that supports long-term maintenance of such CFs.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described herein.
- In describing the embodiments and claiming the invention, the following terminology will be used in accordance with the definitions set out below.
- As used herein, “about” means within 5% of a stated concentration range or within 5% of a stated time frame, unless otherwise specified.
- As used herein, “a medium consisting essentially of” means a medium. that contains the specified ingredients and those that do not materially affect its basic characteristics.
- The terms “defined culture medium,” “defined medium,” and the like, as used herein, indicate that the identity and quantity of each medium ingredient is known. The term “defined,” when used in relation to a culture medium or a culture condition, refers to a culture medium or a culture condition in which the nature and amounts of approximately all the components are known. A culture, composition, or culture medium is “essentially free” of certain reagents, such as signaling inhibitors, animal components or feeder cells, when the culture, composition, and medium, respectively, have a level of these reagents lower than a detectable level using conventional detection methods known to a person of ordinary skill in the art or that these agents have not been extrinsically added to the culture, composition, or medium.
- As used herein, “effective amount” means an amount of an agent sufficient to evoke a specified cellular effect according to the present invention.
- The invention will be more fully understood upon consideration of the following non-limiting Examples. it is specifically contemplated that the methods disclosed are suited for pluripotent stem cells generally. All publications, patents, and patent applications disclosed herein are hereby incorporated by reference as if set forth in their entirety.
- In this Example, we demonstrate the derivation of second heart field progenitors and cardiac fibroblasts from directed differentiation of hPSCs, and the characterization of the hPSC derived CFs (hPSC-CFs) in comparison with human primary cardiac fibroblasts and dermal fibroblasts by morphology, gene expression and functional analysis In addition, the functional assessment by the co-culture of hPSC-CMs and hPSC-CFs is also discussed.
- Methods
- Human Pluripotent Stem Cell Culture: Human iPSC line DF19-9-11T and ESC line H1 and H9-TnnT2-GFP were used in this study. Human PSCs were cultured on Matrigel™ (GFR, BD Biosciences) coated 6-well plates in either mTeSR1 (DF19-9-11 T, H1) medium (WiCell) or E8 (H9-TnnT2-GFP) medium (WiCell) Cells were passaged using Versene solution (invitrogen) every 4-5 days. Cells were washed with PBS and incubated with 1 ml/well Versene solution at 37° C. for 3 minutes, aspirating Versene solution and adding 1 ml/well mTeSR1 or E8 medium to gently pipette up and down to split into cell clusters. Cell clusters were pelleted by centrifugation at 1000 rpm for 3 minutes, and resuspended in mTeSR1™ or E8™ medium, and plated in 6-well plate at the split ratio 1:6 to 1:12
- Differentiation of hPSCs to cardiomyocyes using GiWi protocol: Human PSCs were dissociated with 1 ml/well Versene solution at 37°C. for 5 minutes, and seeded on Matrigel™ coated 6-well plates at the density of 1.5×106 cells/well in mTeSR1 medium supplemented with 10 μM ROCK inhibitor (Y-27632) (Tocris). Cells were cultured for 5-6 days in mTeSR1 medium until the cells reached 100% confluence when differentiation started (day 0) At
day 0, the medium was changed to 2.5 ml RPMI+B27 without insulin (invitrogen) and supplemented with 12 μM CHIR99021 (Tocris) and cells were treated in this medium for 24 hrs (day 1). Atday 1, medium was changed to 3 ml RPMI+B27 without insulin and cells were cultured in this medium for 48 hrs (day 3). 72 hrs (day 3) after addition of CHIR99021, a combined medium was prepared by collecting 1.5 ml of medium from the wells and mixing with same volume of fresh RPMI+B27 without insulin medium and supplemented with 5 μM IWP2 (Tocris), and cells were treated with IWP2 in the medium for 48 hrs (day 5). The medium was changed to 3 ml RPMI+B27 without insulin atday 5. Atday 7 the medium was changed to RPMI+B27 with insulin (Invitrogen), and the cells were fed every other day and cultured untilday 20 for flow cytometry analysis. - Differentiation of hPSCs to cardiac fibroblasts: Human PSCs were dissociated with 1 ml/well Versene solution (Invitrogen) at 37° C. for 5 minutes, and seeded on Matrigel™ (GFR, BD Biosciences) coated 6-well plates at the density of 1.5×106 cells/well in
mTeSR 1. medium supplemented with 10 μM ROCK inhibitor (Y-27632) (Tocris). Cells were cultured for 5-6 days in mTeSR1 medium with medium change daily until the cells reached 100% confluence when differentiation started (day 0). Atday 0, the medium was changed to 2.5 ml RPMI+B27 without insulin (Invitrogen) and supplemented with 12 μM CHIR99021 (Tocris) and cells were treated in this medium for 24 hrs (day 1). Atday 1, medium was changed to 3 ml RPMI+B27 without insulin and cells were cultured in this medium for another day (day 2). Atday 2, the medium was changed to 2.5 ml of the defined fibroblast culture medium (Table 1) supplemented with bFGF (WiCell). Methods using L-glutamine in place of GlutaMAX were also successful Cells were fed every other day and cultured untilday 20 for flow cytometry analysis and subculture of cardiac fibroblasts. -
TABLE 1 Cardiac Fibroblast Differentiation Medium Components Final concentration DMEM, high glucose (4.5 g/L) basal medium HLL Supplement: HSA USA: 500 μg/mL (human serum albumin), Linoleie Acid: 0.6 μM linoleic acid and lecithin Lecithin: 0.6 μg/ mL Ascorbic Acid 50 μg/mL GlutaMAX 7.5 mM Hydrocortisone Hemisuccinate 1.0 μg/ mL rh Insulin 5 μg/mL - Culture of human cardiac fibroblasts and dermal fibroblasts: The hPSC-differentiated cardiac fibroblasts (hPSC-CFs), primary cardiac fibroblasts (Lonza, NHCF-V) and primary dermal fibroblasts (healthy donors, 020a and 023a lines) were used in this study. hPSC-CFs at 20 days differentiation were dissociated with 0.05% Trypsin-EDTA (Invitrogen) and plated in 6-well uncoated plastic plates at the density of 300,000 cells/well in 2 ml of FibroGRO™ medium (Millipore EMD, SCMF001) plus 2% FBS (lnvitrogen). The hPSC-CFs were fed every other day with 2 ml FibroGRO™ medium and passaged every 4-6 days using 0.059% Trypsin-EDTA. The plating density for passaging hPSC-CFs was 5,800 cells/cm2. The primary human CFs were purchased from Lonza Human Cardiac Fibroblasts-Ventricular, CC-2904, lot number 0000401462). The NHCF-V were thawed in FGM-3 medium (Lonza, CC-4526) in uncoated T75 flasks at the density of 3,500 cells/cm2. The cells were fed every other day with the FGM-3 medium, and were passaged every 4-6 days using 0.05% Ttypsin-EDTA. The plating density for passaging NHCF-V was 3,500 cells/cm2. The primary dermal fibroblasts (020a, 023a) were thawed in DMEM high glucose with GlutaMAX™ supplement (Invitrogen 10566-016) plus 10% EBS (Invitrogen 10437) in uncoated 6-well plates at the density of 1,900 cells/cm2. The cells were fed every other day with the same medium as the thawing medium and were passaged every 6-8 days using 0.05% Trypsin-EDTA. The plating density for passaging hDFs was 1,900 cells/cm2.
- How Cytometry: Cells were detached from cell culture plates by incubation with 0.25% trypsin-EDTA (Invitrogen) plus 2% chick serum (Sigma) for 5 minutes at 37° C. Cells were vortexed to disrupt the aggregates followed by neutralization by adding equal volume of EB20 medium (Zhang et al., Circ Res. 2009). Cells were counted and 0.5-1 million cells were used as the sample size for labeling. Cells were fixed in 1% paraformaldehyde in a 37° C. water bath for 10 minutes in the dark. For labeling intracellular markers, cells were permeabilized in ice-cold 90% methanol for 30 minutes on ice. Cells were washed once in FACS buffer (PBS without Ca/Mg2 +, 0.5% BSA, 0.1% NaN3), centrifuged and resuspended in about 50 μl FACS buffer with (for intracellular markers) or without 0.1% Triton X-100. For labeling surface markers, appropriate amounts of the conjugated antibodies were added according to the manufacturer's instruction to the cells in FACS buffer to make the final volume of 100 μl with FACS buffer, and incubated in the dark for 30 minutes at room temperature. Cells were washed once with 3 ml FACS buffer and resuspended in 300-500 μl FACS buffer for analysis. For labeling intracellular markers, the primary antibody was diluted in 50 μl/sample FACS buffer plus 0.1% Triton X-100 (Sigma) and aliquoted to each sample for a total sample volume of 100 μl. Samples were incubated with the primary antibodies overnight at 4° C. (see Table 2). For the secondary antibody labeling, cells were washed once with 3 ml FACS buffer plus 0.1% Triton after the primary antibody labeling, centrifuged, and the supernatant was discarded, leaving ˜50 μl. Secondary antibody specific to the primary IgG isotype was diluted in FACS buffer plus Triton X-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether) in a final sample volume of 100 μl at 11000 dilution. Samples were incubated at room temperature for 30 minutes in the dark, washed in FACS buffer plus Triton X-100 and resuspended in 300 500 μl FACS buffer plus Triton X-100 for analysis. Data were collected on a FACSCalibur™ flow cytometer (Beckton Dickinson) and analyzed using FlowJo™ software.
-
TABLE 2 Primary Antibodies for now Cytometry anti Immunocytochemistry Antibody Supplier (cat#) Species Isotype Concentration Human/Mouse R&D (IC2085P) Goat IgG 10 μl/1 × 106 cells (FC) Brachyury PE- conjugated FITC anti-human Biolegend (328108) Mouse IgG1 5 μl/1 × 106 cells (FC) CD90 Human APLNR R&D (FAB856A) Mouse IgG3 3 μl/1 × 106 cells (live labeling) APC-conjugated (FC) Alexa Fluor 647 BD (560495) Mouse IgG1 20 μl/1 × 106 cells (FC) Mouse Anti- Human CD309 (KDR) PE Mouse Anti- BD (556002) Mouse IgG2a 20 μl/1 × 106 cells (FC) Human CD140a (PDGFRα) FITC Mouse Anti- BD (560984) Mouse IgG1 20 μl/1 × 106 cells (FC) Human CD31 Anti-Feeder-APC Miltenyi Biotec Rat IgG1 1:10 dilution (FC) (Clone mEF-SK4) (130-102-302) Mouse Anti- CBL271 Mouse IgG1 1:100 dilution (FC, ICC) Human Fibroblasts (Clone TE-7) MF20 DSHB Mouse IgG2b 1:20 dilution (FC, ICC) Troponin T, ThermoFisher Mouse IgG1 1:100 dilution (FC, ICC) Cardiac Isoform Scientific Ab-1 (Clone 13-11) (#MS-295-P) Anti-Smooth Biomedical Rabbit IgG 1:500 dilution (FC, ICC) Muscle Myosin Technologies Inc. (BT-562) GATA4 (H-112) Santa Cruz Rabbit IgG 1:200 dilution (ICC) (sc-9053) Anti-Fibroblast- EMD Millipore Rabbit IgG 1:500 dilution (ICC) specific Protein 1 (#ABF32) (S100A4) Fibronectin (A-11) Santa Cruz Mouse IgG2b 1:100 dilution (ICC) (Sc-271098) COL1A (COL1) Santa Cruz Mouse 1gG1 1:100 dilution (ICC) (sc-59772) - Immunocytochemistry: For imaging with a microscope from the EVOS™ line of cell imaging systems (Life Technologies), cells were cultured in either 6-well or 12-wellplates. Cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature, and permeabilized using 0.2% Triton X-100. After permeabilization for about 1 hour at room temperature, cells were blocked with 5% non-fat dry milk (Bio-Rad) in 0.2% Triton X-100 solution and incubated for 2 hours at room temperature on a rotator followed by two washes with PBS. Primary antibodies (Table 2) were added in 1% BSA in PBS solution with 0.1% Triton X-100, and incubated overnight at 4° C. Cells were washed with 0 2
% Tween 20 in PBS twice and 1×PBS twice. Secondary antibodies specific to the primary IgG isotype were diluted (1:1000) in the same solution as the primary antibodies and incubated at room temperature for one hour on a rotator in the dark. Cells were washed with 0.2% Tween 20 in PBS twice and 1×PBS twice. Nuclei were labeled with Hoechst or DAPI - RT-PCR and quantitative RT-PCR: Cell samples were collected using 0.25% trypsin-EDTA (Invitrogen) to remove the cells from cell culture plates. Total RNA was purified using QIAGEN RNeasy® Mini kit. Possible genomic DNA contamination was removed by RNase-Free DNase Set (QIAGEN) with the RNeasy® columns, or by DNase I (Invitrogen) treatment for 15 minutes at room temperature. 500 ng of total RNA was used for an Oligo(dT)20—primed reverse transcription (RT) reaction using SuperScript™ III First-Strand Synthesis System (Invitrogen) Quantitative RT-PCR (Q-PCR) was performed using Taqman PCR Master Mix and Gene Expression Assays (Applied Biosystems) in triplicate for each sample and each gene. 0.5 μl of &DNA from the RT reaction was added as template for each Q-PCR reaction. The expression of genes of interest was normalized to that of GAPDH. RT-PCR was carried out using Platinum™ Taq DNA Polymerase (Invitrogen) or Gotaq Master Mix (Promega). PCR conditions included denaturation at 94° C. for 30 seconds, annealing at. 60° C. for 30 seconds, and extension at 72° C. for 1 minute, for 35 cycles, with 72° C. extension for 7 minutes at the end. The RT-PCR reaction products were subjected to electrophoresis in 2% agarose. ACTB (β-actin) was used as an endogenous control.
- RNA-seq and data analysis: Cell samples were coilected using 0.25% trypsin-EDTA (Invitrogen) to remove the cells from cell cultum plates. Total RNA was purified using QIAGEN RNeasy® Mini kit. Possible genomic DNA contamination was removed by RNase-Free DNase Set (QIAGEN) with the RNeasy columns. Duplicates for each sample were submitted for RNA-seq Total RNA was qualified with the Life Technologies Qubit fluorometer (Q32857) and Agilent Bioanalyzer (G2940CA). One-hundred nanograms of total RNA was used to prepare indexed cDNA libraries with the Ligation Mediated Sequencing (LM-Seq) protocol (Hon Z et al.,
Scietific Repprts 5, 2015). Final indexed cDNA libraries were pooled with thirty uniquely indexed LM-Seq cDNA libraries per lane and sequenced on an Illumina HiSeq 2500 with a single 51-bp read and a 10-hp index read. Base-calling and demultiplexing were performed using Casava (v1.8.2). Sequences were filtered and trimmed to remove low quality reads, adapters, and other sequencing artifacts. The remaining reads were aligned to 19084 Refseq genes extracted from the Illumina iGenomes reference, selecting only those with‘NM_’ annotations. Bowtie(v 0.12.9) was used for alignment, allowing two mismatches in a 28 bp seed (Langmead et al., Genome Biol. 2009; 10:R25. Reads with more than 200 alignments were excluded from futher analysis. RSEM (v1.2.3) was used to estimate isoform and relative gene expression levels (transcripts per million or “TPM”) (Li et al., BMC Bioinformatics. 2011;12:323). - Extracellular matrix production and confocal imaging: Confluent hPSC-CFs, primary human CFs, and dermal fibroblast were dissociated with TrypLE™ reagent (a reagent free of animal- and human-derived components; Thermo Fisher) and seeded onto 6-well plates at the density of 1.25×106 cells well. Cells were grown for 10 days with medium change every other day. hPSC-CFs were grown with FibroGRO™ medium (Millipore EMD, SCMF001) plus 2% FBS (Invitrogen), primary human CFs (NHCF-V) were grown in FGM-3 medium (Lonza), and dermal fibroblasts were grown with DMEM high glucose with GlutaMAX™ supplement (Invitrogen) plus 10% FBS (Invitrogen) medium. On
day 10, cells for imaging were fixed with 4% paraformaldehyde for 15 minutes at room temperature, and stored in PBS at 4° C. For a total collagen assay, cells were treated using a modified decellularization protocol by Schmuck et al., Cardiovascular Engineering and Technology 5(1):119-131 (2014). The extracellular matrix proteins including collagen and fibronectin were co-labeled with anti-COL1A (COL-1) (Santa Crutz Biotechnology, sc-59772) and anti-Fibronectin (A-11) (Santa Crutz Biotechnology, sc-271089) antibodies without permeabilization of the cells to examine the extracellular matrix using the immunolabeling protocol in the ‘Immunocytochemistry’section. Cells were imaged using the confocal microscope (Leica TCS SP5 system). - Co-cultures hPSC-CM and hPSC-CF or hPSC-CF or hPSC-CM and hDF: hPSC-CMs were cultured with either hPSC-CFs or hDFs at varying percentages: 100%, 90%, 70%, 50% or 0%. These co-cultures were plated at a density of 250,000 cells per 200 ul drop of EB20 (80% DMEM/F12, 0.1 .mmol/L nonessential amino acids, 1 mmol/L 1-glutamine, 0.1 mmol/L β-mercaptoethanol, 20% FBS and 10 μmol/L blebbistatin) on 18×18 mm pieces of polydimethylsiloxane (PDMS) silicone sheeting (SMI; Saginaw, Mich.) coated with Matrigel™ (500 μg/mL, Corning) and grown for 3 days kept at 37° C. in 5% CO243. At this point the medium was changed to RPMI (Gibco) supplemented with B27 (Gibco) and replaced every two days for 4 days prior to experimentation.
- Optical Mapping: Optical action potentials and time space plots were recorded using FIuroVolt™ membrane potential probe (F10488, Life Technologies).43-46 After a 30 minute incubation period, monolayers were transferred to Hank's balanced salt solution HBSS with calcium and magnesium, Gibco) for optical mapping recording and kept at 37° C. for the duration of the experiment. All monolayers containing hPSC-CMs displayed spontaneous pacemaker activity which was recorded using a CCD camera (Red-Shirt Little Joe, Scimeasure, Decatur, Ga., 80×80 pixels) with the appropriate emission filters and LED illumination44. Ten second movies were taken at 200 fps (LabWindows Acquisition, National Instruments, Austin, Tex., USA) which were amplified, filtered and digitized for offline analysis. Movies were filtered in both the time and space domain and action potential duration (APD) and conduction velocity (CV) were measured as previously describes45,46. Repetitive stimuli (duration, 5 ms; strength, twice diastolic threshold) was applied by field stimulation using silver electrodes. Monolayers were paced faster than the spontaneous beating rate, which was different depending on the co-culture with hDFs or hPSC-CFs (
FIGS. 5C-5D ). Overlapping stimulation frequencies for each condition were obtained at cycle lengths of 400, 333.3 and 285.7 ms. - Statistim Data are presented as mean±standard error of the mean (SEM). For datasets with normal distributions, statistical significance was determined by Student's t-test for two groups or one-way ANOVA for multiple groups with post-hoc test using Bonferroni and Tuley method. Statistical analysis was performed using Origin, v9, P<0.05 was considered statistically significant.
- Results
- During embryonic development, CFs arise starting at midgestation from multiple sources. The epicardium is the major source of CFs found in the ventricular myocardium with epicardial progenitors undergoing an epithelial to mesenchymal transition requiring expression of TCF21 to generate CFs14-17. In addition, another population of CFs has been identified in the heart derived from the endocardium at the time of endocardial cushion formation by an endothelial-to-mesenchymal transition18, 19. These endocardial-derived CFs contribute the cardiac valves and populate the interventricular septum to the greatest extent. Lastly, a small fraction of fibroblasts, mostly present in the right atrium, are derived from neural crest lineages20. Given that cardiac lineages are primarily derived from mesoderm, we hypothesized that manipulating cellular signaling impacting hPSC-derived mesodermal committed progenitors could efficiently lead to the generation of liPSC-CFs.
- Biphasic modulation of the Wnt signaling pathway with small molecules is sufficient to direct the differentiation of monolayer cultured hPSCs to cardiomyocytes21. Activation of canonical. Wnt signaling by GSK3β inhibition stimulates hPSCs to sequentially form mesoderm and cardiac progenitors that are subsequently induced to differentiate to cardiomyocytes by inhibition of Wnt signaling. We first determined the stage-specific mesodermal and cardiac progenitor populations generated by this small molecule (GiWi) protocol22. Flow cytometry demonstrated that the early mesodermal marker Brachyury was. expressed in almost all cells after 24 hours of treatment with CHIR. Expression of Brachyury was present for another 24 hours before it was quickly downregulated after day 2 (
FIGS. 1A-1B ). CD90 was robustly expressed in hPSCs, but its expression gradually declined during the differentiation. Most of the cells expressed CD90 at days 2-3 (>80%) but the expression level of CD90 was relatively lower than in hPSCs (FIG. 1B ). This Brachyuryddown/CD90low progenitor stage first showed upregulation of MESP1 mRNA expression (FIG. 2B ) which is expressed in cardiac mesodermal progenitors. The apelin receptor (APLNR) is expressed in early mesodermal progenitors importantly including lateral plate mesodermal cells specified to be cardiac progenitors as well as APLNR+ cells that have the potential to give rise to mesenchymal stem cells (MSCs) and endothelial cells23-26, APLNR expression was first seen atday 3, and APLNR+ cells peaked at 66% of the cells onday 4 and then rapidly declined (FIG. 1B ). KDR+/PDGFRα+ cells have been identified as cardiac progenitor cells (CPCs) that can be differentiated mainly to cardiomyocytes in the cardiac differentiation of hPSCs11. We found the KDR+/PDGFRα+CPCs were mainly generated on day 4-5 (FIGS. 1A-1B ). These stage-specific progenitors were reproducibly generated from other hPSC lines using the GiWi protocol (FIG. 5 )22. - Because prior studies have demonstrated that FGF signaling contributes to the generation of cardiac mesodermal progenitors and exerts a dominant effect over BMP signaling directing cardiac mesodermal progenitors to nonmyocyte fates27, 28, we tested the impact of FGF signaling on progenitors present following activation of canonical Wnt signaling by CHIR (
FIG. 1C ). Our goal was to bias the differentiation to generate cardiac fibroblasts rather than cardiomyocytes. We tested a range of concentrations of bFGF (0-125 ng/ml) in a defined medium for fibroblast growth (CFBM, Table 1) at different progenitor stages in the GiWi protocol (FIGS. 1C-1D ) Following 20 days of differentiation, cells were analyzed by flow cytometry using a specific fibroblast antibody (mouse anti-human fibroblast, clone TE-7) and an antibody to sarcomeric myosin (MF20) expressed in cardiomyocytes. Changing the medium and adding bFGF onday 2 orday 3 effectively prevented the generation of MF+ cardiomyocytes, and there was a concentration-dependent increase in fibroblast marker positive cells, which peaked at 75 lig/nil bRif added onday 2 of differentiation (FIG. 1D ). At higher concentration of bFGF when added onday 3 orday 4, significant cell death resulted afterday 6 of differentiation and no cells survived at 20 days (FIG. 1D ). Thus applying a fixed concentration of 75 ng/ml of bFGF to cardiac mesodermal progenitors in a context-dependent fashion generated large population of putative CFs in both the human iPS cell line DF 19-9-11T and the ES cell line H1 (FIG. 1E ). - We refer to the protocol of adding 75 ng/ml of bFGF in CFBM medium starting on
day 2 following CiSK3β inhibition (Gi) as the GiFGF protocol (FIG. 2A ). To understand the impact of bFGF on the differentiation ofday 2 mesodermal progenitors in the GiFGF protocol, we examined the temporal gene expression pattern for developmentally regulated transcription factors and associated genes using quantitative RT-PCR (FIGS. 2A-2B ;FIGS. 7A-7B ). The early mesodermal gene T was transiently up-regulated after the CiSK3p inhibitor (CHIR) treatment peaking atday 1, which is consistent with the transient expression of T during the primitive streak in development as well as the observations from other in vitro cardiac differentiation protocols27, 29, and our flow cytomeny data (FIG. 1B ).MES 1 and GATA4 started to express onday 2 of differentiation following the expression of T, indicating onset of cardiac mesodermal progenitors. Next, the cardiac-related transcription factors were upregulated following bFGF treatment including ISL1, TBX1, GATA4, NKX2.5, HAND2 (FIG. 2B andFIGS. 7A-7B ). The expression ISL1, GATA4 and HAND2 remained high through 20 days of differentiation. Interestingly, the pattern of expression is consistent with the formation of second heart field (SHF) progenitors given the prominent expression of ISL1, TBX1, GATA-4 and HAND230-33. These results contrast the cardiomyocyte-optimized GiWi protocol in which transcription factors associated with first heart field (FHF) progenitors including TBX534, HAND1 and MX20 are more prominently expressed (FIG. 7A ). In addition, the ion channel gene, HCN4, which is recognized as the FHF progenitor market35, is minimally expressed in the GiFGF protocol compared to the GiWi protocol (FIG. 2B andFIG. 7A ). TCF21, a bHLH transcription factor required for the formation of CF in mouse heart16, was progressively upregulated from day 6-20 in the GiFGF protocol (FIG. 2B andFIG. 7B ). However, we did not observe a significant upregulation of epicardial progenitor genes such as TBX18 and WT1 in the FGF directed CFs differentiation (FIG. 2B andFIG. 7B ), consistent with the findings that FGF signaling inhibited (pro)epicardium differentiation from the cardiac mesoderm27. We also examined the EMT markers of SNAI1 and SNAI2 in the GiFGF protocol and found an early upregulation of SNAI1 (day 2-3) and a late upregulation of SNAI2 (day 6-20) (FIG. 2B ), consistent with their differential roles in promoting EMT36, in which SNAI1 promotes mesoderm formation by downreadation of ectodermal gene expression, while SNAI2 represses E-cadherin expression during the EMT in CFs differentiation. VIM, a common fibroblast marker, was greatly upregulated during CF differentiation (FIG. 2C ). In contrast, TNNT2, a typical cardiomyocyte marker, is minimally expressed in the GiFGF protocol (FIG. 2C ). Furthermore, POSTN, a gene expressed in cardiac fibroblasts37, was also greatly upregulated by 20 days differentiation in the GiFGF protocol, whereas the general fibroblast-associated DDR2 gene showed smaller fold change compared to POSTN (FIG. 2C ). To screen for gene expression typical of endothelial or smooth muscle cells, we examined PeCAM1 (CD31) and MYHI1 (smooth muscle myosin heavy chain) expression and found there was very low expression of PECAM1 and essentially no expression of MYHI1 in the GiFGF protocol (FIG. 2C ). Finally, THY1 (CD90) expression was high in the undifferentiated stem cells, but downregulated during CFs differentiation (FIG. 2C ). Given that high bFGF concentrations can be supportive of maintenance of pluripotency, we examined the expression of the pluripotency gene OCT4 and showed it to be completely downregulated during the CF differentiation (FIG. 2C ), similar to the downregulation observed in cardiomyocyte differentiation protocols12, 21, 29. - We next compared the properties of hPSC-CF populations with human primary adult cardiac fibroblasts (NHCF-V, Lonza) and dermal fibroblasts (hDF) The morphology of hPSC-CF, NHCF-V and hDF maintained in similar media was comparable with spindle-shaped and polygonal cells present (
FIG. 3A ). The hPSC-CF can propagate for at least 10 passages before undergoing senescence similar to primary CFs (FIG. 3B ). The expression of CD90 (THY1), which has been used as a cell surface marker for some fibroblasts populations, was uniformly expressed on hDF and maintained over multiple passages (FIG. 3C andFIG. 8 ) in contrast, expression of CD90 was present on only a fraction of hPSC-CF or FINCF-V (22-40%) and was present on a progressively smaller percentage of cells with passaging. Notably, the hPSC-CFs and HNCF-V showed a similar change in expression of this surface marker over passages. The hDF were also uniformly positive for an intracellular fibroblast marker (clone TE-7)38, and the hPSC-CF and NHCF-V showed that 65-90% of the cells were positive at early passage, and the purity increased to 75-99% with subsequent passaging (FIG. 3D andFIG. 9 ). Thus, the hPSC-CFs and NHCF-V populations share similar expression patterns of fibroblast markers over sequential passaging which is distinct from hDFs. - We also examined the cell preparations for markers of other related cell lineages including CD31 (endothelial), SM-MHC (smooth muscle) and MF20 (cardiomyocytes) by flow cytometry in comparison to the GiWi cardiomyocyte protocol. Unlike the GiWi protocol which generated MF20+ cardiomyocytes as the majority of cells, the GiFGF protocol produced very few MF20+ cardiomyocytes (0.8%) which became progressively less with passaging (
FIG. 3E ). A small ˜5% SM-MHC+ population of cells was detected in the GiWi protocol, but a much smaller percentage was present with GiFGF which declined with passaging. None of the protocols produced clearly measurable numbers of CD31+ endothelial cells. - Immunolabeling of the cell preparations was performed to evaluate for other proteins associated with fibroblasts. importantly, the TE-7-labeled fibroblasts from hPSC-CFs and NHCF-V were all GATA4 positive, which has been reported specifically in cardiac fibroblasts relative to fibroblasts from other tissues7, but GATA4 was not detected in the primary hDF (
FIG. 3F ). There were no cTnT positive cardiomyocytes detected in any of the fibroblast cell lines (FIG. 3F ). Immunolabeling for FSP1, another protein associated with fibroblasts, was detected in the majority of cells from all three preparations and likewise, the extracellular matrix proteins collagen and fibronectin were expressed across the preparations (FIG. 3G ). Thus, while hPSC-CFs share some properties with both hDFs and NHCF-V, they are most similar to NHCF-V in their marker expression and particularly in the expression of GATA4. - To characterize the gene expression pattern in hPSC-CFs, we performed RNA-secs on hPSC-CFs and compared the total mRNA transcripts with those of NHCF-V, hDF, hPSC-differentiated cardiomyocytes (hPSC-CM), and hPSC. Statistical analysis of gene expression across all the samples from the RNA-seq results showed the greatest similarity in the abundance of overall transcripts (19,084) between hPSC-CFs and primary CFs (NHCF-V) calculated by Euclidean distance (
FIG. 4A ). Gene Ontology analysis using the online tool AmiGO2 for cardiac-related genes (57) from the RNA-seq results demonstrated enriched cardiac factors in hPSC-CF, NHCF-V and hPSC-CM which clustered together relative to the hDF and hPSC samples (FIG. 4B ). For example, hPSC-CF and NHCF-V showed relatively higher expression of BMP-4,GATA4, HAND2, HEY1, ISL1, NKX2.5SOX17 and WT1 relative to hDF (FIG. 4B ). We also analyzed the ECM related gene expression in all samples given the importance of ECM production in fibroblast biology. High expression ofcollagen FIG. 4C ) in summary, the RNA-seq data show that hPSC-CF and NHCF-V have the most similar gene expression pattern overall and specifically for cardiac-related genes and matrix genes. - Generation of ECM is a major function of CFs. Therefore, we examined the 3D structure of the ECM scaffolds generated by the hPSC-CF in comparison with the primary CF (NHCF-V) and hDF following 10 days of high-density culture39. The cultures were fixed and immunolabeled with anti-collagen IA and anti-human fibronectin antibodies, and nuclei were stained with Hoechst. Confocal imaging demonstrated that all three fibroblast preparations robustly produced collagen I and fibronectin (
FIG. 4D ). However, 3D reconstructions demonstrated that the hPSC-CF and NHCF-V produced multi-cell layer cultures while the hDF produced only monolayer cultures. This was also reflected in the greater thickness of the hPSC-CF (˜35 μm) and NHCF-V cultures (˜21 μm) relative to the hDF cultures (˜10 μm) (FIG. 4E ). Furthermore, both the hPSC-CF and NHCF-V resulted in polarized matrix production with fibronectin concentrated at the top of the culture in contrast to the hDF culture which showed fibronectin and collagen I labeling equivalently throughout the depth of the culture (FIG. 4D ). Overall, the hPSC-CF in. high-density culture generate an ECM scaffold in a similar fashion to NHCF-V which is distinct from that of hDF cultures. - Given that CFs can influence the electrophysiological properties of the native heart particularly in disease, we examined the functional impact of the co-culture of hPSC-CFs with hPSC-CMs, compared to the co-culture of hDFs with hPSC-CMs. Various ratios of tiPSC-CMs and fibroblasts were co-cultured, and representative images confirm different co-culture proportions using immunofluorescent staining for cTnT (green) to label hPSC-CMs and DAPI to. label the nuclei of all cells (
FIG. 5A ). In functional experiments, co-cultured monolayers were labelled with membrane potential dye (FluoVolt) to quantify electrophysiological effects of hPSC-CFs and hDFs on the spontaneous electrical impulse propagation. Time-space plots of action potential propagation (FIG. 5B ) show the differential impact of each fibroblast subtype on hPSC-CM. monolayer function. The presence of 10% hDFs decreased the spontaneous rate of cardiac monolayers by more than 50% relative to 100% hPSC-CMs, whereas 10% hCF did not have significant effect on the spontaneous rate. Impulse conduction velocity was slowed significantly with 10% of either type of fibroblast, although to a greater extent in the hDF co-culture (FIGS. 5B-5C ). Interestingly, at a ratio of 50% hPSC-CMs:50% hPSC-CFs, we observed fibrillatory conduction patterns in all of the monolayer co-cultures tested (6/6) while the same ratio using hDFs did not induce this arrhythmia pattern in any monolayer co-cultures tested (0/6) (FIGS. 5B-5C ). To match the electrical activation rate for each condition, we used field stimulation and constructed APD restitution curves for the monolayer co-cultures. 10% hDF monolayer co-cultures had significantly longer APD80 than 10% hPSC-CF monolayer co-cultures when pacing rate was matched (cycle lengths 400, 333.3 and 287.5 ms). These data suggest that hDF and hPSC-CFs have distinct influence on hPSC-CM monolayer function, consistent with tissue-specific fibroblast functional properties. - Overall, our data demonstrate that hPSCs can be efficiently differentiated to CFs by sequential activation of Wnt and FGF signaling to promote mesodermal, cardiac mesodermal and SHF progenitors leading to the efficient generation of CFs. The hPSC-CFs share characteristics with native CFs based on gene expression, matrix production and the distinct modulation of hiPSC-CM electrophysiology. Access to an unlimited supply of hPSC-CFs will empower research in heart development and disease modeling, as well as efforts in drug discovery and tissue engineering.
- All publications, including but not limited to patents and patent applications, cited below are herein incorporated by reference as though set forth in their entirety in the present application.
- 1. Zeisberg, E. M. & Kalluri, R. Origins of cardiac fibroblasts. Circ Res 107, 1304-1312 (2010).
- 2. Lajiness, J. D. & Conway, S. J. The dynamic role of cardiac fibroblasts in development and disease, J
Cardiovasc Transl Res 5, 739-748 (2012). - 3. Souders, C. A., Bowers, S. L. & Baudino, T. A. Cardiac fibroblast: the renaissance cell Circ Res 105, 1164-1176 (2009).
- 4. Camelliti, P., Borg, T. K. & Kohl, P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65, 40-51 (2005).
- 5. Porter, K. E. & Turner,. N. A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123, 255-278 (2009).
- 6. Brown, R. D., Ambler, S. K., Mitchell, M. D. & Long, C. S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu
Rev Pharmacol Toxicol 45, 657-687 (2005). - 7. Furtado, M. B. et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res 114, 1422-1434 (2014).
- 8. Ieda, M. et al. Cardiac fibroblasts regulate myocardial proliferation through ketal integrin signaling. Developmental cell 16, 233-244 (2009).
- 9. D'Souza, K. M. et al. G protein-coupled receptor kinase-2 is a novel regulator of collagen synthesis in adult human cardiac fibroblasts. J Bio Chem 286, 15507-15516 (2011).
- 10. Kohl, P. & Gourdie, R. G. Fibroblast-myocyte electrotonic coupling: does it occur in native cardiac tissue? J
Mol Cell Cardiol 70, 37-46 (2014). - 11. Kaman, S. J. et al. Stage-specific optimization of activinlnodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228-240 (2011).
- 12. Zhang, J. et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method.
Circ Res 111, 1125-1136 (2012). - 13. Witty, A. D. et al. Generation of the epicardial lineage from human pluripotent stem cells.
Nat Biotechnol 32, 1026-1035 (2014). - 14. Cai, C. L. et al. A myocardial lineage derives from Tbx18 epicardial cells. Nature 454, 104-108 (2008).
- 15. Smith, C. L., Baek, S. T., Sung, C. Y. & Tallquist, M. D. Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ Res 108, e15-26 (2011).
- 16. Acharya A. et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139, 21.39-2149 (20121).
- 17. Mikawa, T. & Gourdie, R. G. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev Biol 174, 221-232 (1996).
- 18. Wessels, A. et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev Biol 366, 111-124 (2012).
- 19. Moore-Morris, T. et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest 124, 2921.-2934 (2014).
- 20. Ali, S. R. et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ Res 11.5, 625-635 (2014).
- 21. Lian, X. et at Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America 109, E1848-1857 (2012).
- 22. Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8, 162-175 (2013).
- 23. Vodyanik, M. A. et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells.
Cell Stem Cell 7, 718-729 (2010). - 24. Zeng X. X., Wilm, T. P., Sepich, D. S. & Solnica-Krezel, L. Apelin and its receptor control heart field formation during zebrafish gastrulation. Developmental cell 12, 391-402 (2007).
- 25. Scott, I. C. et al. The g protein-coupled receptor agtrl -lb regulates early development of myocardial progenitors. Developmental cell 12, 403-413 (2007).
- 26. D'Aniello, C. et al. G protein-coupled receptor API and its ligand apelin act downstream of Cripto to specify embryonic stem cells toward the cardiac lineage through extracellular signal-regulated kinase/p70S6 kinase signaling pathway. Circ Res 105, 231-238 (2009).
- 27. Loh, K. M. et al Mapping the Pairwise Choices Leading from. Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types. Cell 166, 451-467 (2016).
- 28. van Wijk, B. et al. Epicardium and myocardium separate from a common precursor pool by crosstalk between bone morphogenetic protein- and fibroblast growth factor-signaling pathways. Circ Res 105, 431-441 (2009).
- 29. Yang, L et al. Human cardiovascular progenitor cells develop from a K.DR-E-embryonic-stem-cell-derived population. Nature 453, 524-528 (2008).
- 30. Cai, C. L. et al. Isi1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart.
Dev.Cell 5, 877-889 (2003). - 31. Xu, H. et al. Tbx1 has a dual role in the morphogenesis of the cardiac outflow tract. Development 131, 3217-3227 (2004).
- 32. Bu, L. et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460, 113-117 (2009).
- 33. Tsuchihashi, T. et al. Hand2 function in second heart field progenitors is essential for cardrogenesis. Dev Biol 351, 62-69 (2011).
- 34. Br peau, B. G. et al. Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev Biol 211, 100-108 (1999).
- 35. Spater, D. et at A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells.
Nat Cell Biol 15, 1098-1106 (2013). - 36. VillarejoA., Cortes-Cabrera, A., Molina-Ortiz, P., Portillo, F. & Cano, A. Differential role of Snail1 and Snail2 zinc fingers in E-cadherin repression and epithelial to mesenchymal transition. J Biol Chem 289, 930-941 (2014).
- 37. Snider, P. et al. Origin of cardiac fibroblasts and the role of periostin. Circ Res 105, 934-947 (2009).
- 38. Kaaya, E. E. et al. Heterogeneity of spindle cells in Kaposi's sarcoma: comparison of cells in lesions and in culture. J Acquir Immune Defic
Syndr Hum Retrovirol 10, 295-305 (1995). - 39. Schmuck, E. G. et al. Cardiac fibroblast-derived 31D extracellular matrix seeded with mesenchymal stem cells as a novel device to transfer cells to the ischemic myocardium. Cardiovascular engineering and
technology 5, 119-131 (2014) - 40. Zhang, J. et al. Functional cardiomyocytes derived from human induced pluripotent stern cells. Circ Res 104, e30-41 (2009).
- 41. Langinead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Genome Biol 10, R25 (2009). - 42. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
- 43. Herron, T. J., et al. Extracellular Matrix-Mediated Maturation of Human Pluripotent Stem Cell-Derived Cardiac Monolayer Structure and Electrophysiological Function. Circulation. Arrhythmia and
electrophysiology 9, e003638 (2016). - 44. Lee, P. et al. Single-sensor system for spatially resolved, continuous, and multiparametric optical mapping of cardiac tissue. Heart Rhythm 8, 1482-1491 (2011).
- 45. Morley, G. E. et al. Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping.
J Cardiovasc Electrophysiol 10, 1361-1375 (1999) - 46. Zaitsev, Berenfeld, O., Mironov, S. F., Jalife, J. & Pertsov, A. M. Distribution of excitation frequencies on the epicardial and endocardial surfaces of fibrillating ventricular wall of the sheep heart.
Cure Res 86, 408-417 (2000). - The present invention has been presented by way of illustration and is not intended to be limited to the disclosed embodiments. Accordingly, those skilled in the art will realize that the invention is intended to encompass all modifications and alternative arrangements within the spirit and scope of the invention as set forth in the appended claims.
Claims (14)
1-10. (canceled)
11. A method for generating a human arrhythmia model, the method comprising the steps of:
co-culturing a population of cardiac fibroblast cells in the presence of a population of cardiomyocytes in a chemically defined culture medium.
12. The method of claim 11 , wherein the cardiac fibroblast cells are generated by a method comprising culturing human cardiac mesoderm progenitor cells in a chemically defined culture medium comprising a fibroblast growth factor, whereby a cell population comprising human cardiac fibroblast cells is obtained after about 20 days in culture.
13. The method of claim 11 , wherein the co-culture comprises 10%, 50%, 70%, or 90% cardiac fibroblast cells.
14. The method of claim 11 , wherein the co-culture is seeded at a density between about 60,000 cells/cm2 and about 120,000 cells/cm2.
15. A method of screening a test agent, the method comprising:
co-culturing a population of cardiac fibroblast cells in the presence of a population of cardiomyocytes in a chemically defined culture medium;
contacting the co-culture with a test agent;
measuring a functional parameter of the contacted co-culture; and
comparing the functional parameter to that parameter measured in a co-culture which has not been contacted with the test agent, wherein modulation of the functional parameter after contact with the test agent indicates the test agent is a candidate therapeutic agent.
16. The method of claim 15 , wherein the test agent is selected from the group consisting of (i) an organic compound; (ii) a nucleic acid; (iii) a peptide; (iii) a polypeptide; and
(iv) an antibody.
17. The method of claim 15 , wherein the functional parameter is selected from the group consisting of electrical impulse propagation pattern, conduction velocity, and action potential duration.
18. The method of claim 18 , wherein the electrical impulse propagation pattern is measured using a fluorescent membrane potential dye.
19. The method of claim 17 , wherein acceleration of the conduction velocity after contact with the test agent indicates the test agent is a candidate therapeutic agent.
20. The method of claim 17 , wherein prolongation of the action potential duration after contact with the test agent indicates the test agent is a candidate therapeutic agent.
21. The method of claim 17 , wherein the electrical impulse propagation pattern is measured as the fibrillatory or reentry pattern and an increase in the pattern after contact with the test agent indicates the test agent is a candidate therapeutic agent.
22. The method of claim 15 , wherein the cardiac fibroblast cells are generated by a method comprising culturing human cardiac mesoderm progenitor cells in a chemically defined culture medium comprising a fibroblast growth factor, whereby a cell population comprising human cardiac fibroblast cells is obtained after about 20 days in culture.
23. A kit for differentiating human pluripotent stem cells into cardiac fibroblasts, the kit comprising: (i) a chemically defined culture medium suitable for differentiating human cardiac progenitor cells into cardiac fibroblasts; (ii) an agent that activates Wnt signaling in human cardiac progenitor cells; (iii) a fibroblast growth factor; and (iv) instructions describing a method for generating human CFs, the method employing the culture medium, the agent, and the fibroblast growth factor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/345,773 US20210363487A1 (en) | 2016-09-30 | 2021-06-11 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662402694P | 2016-09-30 | 2016-09-30 | |
US15/720,657 US11072780B2 (en) | 2016-09-30 | 2017-09-29 | Method of differentiating human pluripotent cells into cardiac fibroblasts |
US17/345,773 US20210363487A1 (en) | 2016-09-30 | 2021-06-11 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/720,657 Division US11072780B2 (en) | 2016-09-30 | 2017-09-29 | Method of differentiating human pluripotent cells into cardiac fibroblasts |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210363487A1 true US20210363487A1 (en) | 2021-11-25 |
Family
ID=61757808
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/720,657 Active US11072780B2 (en) | 2016-09-30 | 2017-09-29 | Method of differentiating human pluripotent cells into cardiac fibroblasts |
US17/345,773 Pending US20210363487A1 (en) | 2016-09-30 | 2021-06-11 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/720,657 Active US11072780B2 (en) | 2016-09-30 | 2017-09-29 | Method of differentiating human pluripotent cells into cardiac fibroblasts |
Country Status (1)
Country | Link |
---|---|
US (2) | US11072780B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210284965A1 (en) * | 2018-07-13 | 2021-09-16 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072780B2 (en) * | 2016-09-30 | 2021-07-27 | Wisconsin Alumni Research Foundation | Method of differentiating human pluripotent cells into cardiac fibroblasts |
US20220348877A1 (en) * | 2019-06-28 | 2022-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis |
JP2023515681A (en) * | 2020-03-02 | 2023-04-13 | ザ ジェイ. デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デビッド グラッドストーン | Regulation of fibroblast activation to prevent fibrosis |
EP3945133A1 (en) | 2020-07-29 | 2022-02-02 | Georg-August-Universität Göttingen | Mass production of human pluripotent stem cell derived cardiac stromal cell |
CN114149964A (en) * | 2021-12-29 | 2022-03-08 | 中国人民解放军陆军军医大学 | Method for separating and extracting fiber cells from mouse heart |
CN114350602B (en) * | 2022-01-05 | 2024-02-02 | 中山大学附属第五医院 | Cavernous body fibrosis disease model, and construction reagent and construction method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072780B2 (en) * | 2016-09-30 | 2021-07-27 | Wisconsin Alumni Research Foundation | Method of differentiating human pluripotent cells into cardiac fibroblasts |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5734998A (en) | 1997-01-10 | 1998-08-03 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
WO2006029084A2 (en) * | 2004-09-03 | 2006-03-16 | Cornell Research Foundation, Inc. | Bone marrow derived oct3/4+ stem cells |
GB2447191B (en) * | 2005-12-22 | 2011-08-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
WO2008058216A2 (en) * | 2006-11-07 | 2008-05-15 | Keck Graduate Institute | Enriched stem cell and progenitor cell populations, and methods of producing and using such populations |
GB201109882D0 (en) * | 2011-06-13 | 2011-07-27 | Cambridge Entpr Ltd | Population of smooth muscle cells of specific embryonic lineages |
-
2017
- 2017-09-29 US US15/720,657 patent/US11072780B2/en active Active
-
2021
- 2021-06-11 US US17/345,773 patent/US20210363487A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072780B2 (en) * | 2016-09-30 | 2021-07-27 | Wisconsin Alumni Research Foundation | Method of differentiating human pluripotent cells into cardiac fibroblasts |
Non-Patent Citations (3)
Title |
---|
Campbell (Turksen, K [Editor]. Methods in Molecular Biology, pp. 51-59. Stem Cell Niche, 2 Edition:Methods and Protocols) * |
Lian (Nature protocols, 2013, Vol. 8, No. 1, pg 162-175). * |
Xu (Stem cells and Develop., 2006, Vol. 15, pg 931-941). * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210284965A1 (en) * | 2018-07-13 | 2021-09-16 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
Also Published As
Publication number | Publication date |
---|---|
US11072780B2 (en) | 2021-07-27 |
US20180094245A1 (en) | 2018-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210363487A1 (en) | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells | |
Zhang et al. | Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors | |
US20210062153A1 (en) | Methods and compositions for generating epicardium cells | |
Cao et al. | Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells | |
Van Vliet et al. | Early cardiac development: a view from stem cells to embryos | |
Rajala et al. | Cardiac differentiation of pluripotent stem cells | |
US11591569B2 (en) | Methods for epicardial differentiation of human pluripotent stem cells | |
US9068167B2 (en) | Cardiac differentiation of human pluripotent stem cells under defined conditions using matrix overlay methods | |
WO2013063305A2 (en) | Directed cardiomyocyte differentiation of stem cells | |
JPWO2019093340A1 (en) | Method for inducing primitive endoderm from naive pluripotent stem cells | |
EP3828262A1 (en) | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same | |
JP2018531597A (en) | Method for differentiating induced pluripotent stem cells produced from adult endocardial stem cells into cardiovascular cells and uses thereof | |
US20200231933A1 (en) | Human pluripotent stem cell derived endocardial endothelium | |
JP7274683B2 (en) | METHOD FOR GENERATING KIDNEY CONSTRUCTION WITH DENDRITIC DRANGED COLLECTING ductS FROM PLIPOTENTIAL STEM CELLS | |
JP2017108705A (en) | Cardiomyocyte production method | |
Floy et al. | Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine | |
WO2020203712A1 (en) | Method for producing pluripotent stem cells capable of differentiating into specific cells, and application thereof | |
Moccia et al. | Embryonic stem cells for cardiac regeneration | |
Raju | Factors involved in cardiogenesis | |
WO2020095423A1 (en) | Method for producing kidney structure having dendritically branched collecting duct from pluripotent stem cells | |
Engel | Harnessing the Power of Human Embryonic Stem Cells and Direct Reprogramming for Cardiac Regeneration | |
Pekkanen-Mattila | Cardiomyocyte differentiation from human pluripotent stem cells | |
Witty | The Derivation of the Myocardial, Epicardial and Endocardial Lineages from Human Pluripotent Stem Cells | |
Guddati | Derivation of cardiomyocytes from embryonic stem cells and development of techniques to study cardiac lineage | |
Ikäheimo | Differentiation of human pluripotent stem cells into cardiomyocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION, WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAMP, TIMOTHY;ZHANG, JIANHUA;SIGNING DATES FROM 20180112 TO 20180116;REEL/FRAME:056557/0129 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |